

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number
WO 2004/089983 A2

(51) International Patent Classification: C07K 14/65,
C12N 15/85, 5/10, C07K 16/10, C12Q 1/70, G01N
33/569, A61K 39/215, 38/21

(74) Agent: WINCKELS, J., H., F.; Nieuwe Parklaan 97,
NL-2587 BN Den Haag (NL).

(21) International Application Number:
PCT/NL2004/000229

(22) International Filing Date: 8 April 2004 (08.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03076037.5 8 April 2003 (08.04.2003) EP
03076110.0 14 April 2003 (14.04.2003) EP
03077307.1 18 July 2003 (18.07.2003) EP

(71) Applicant (for all designated States except US): VI-
RONOVATIVE B.V. (NL/NL); Burgemeester Oudlaan
50, NL-3062 PA Rotterdam (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HAAGMANS,
Bartholomeus, Leonardus (NL/NL); Doude van Troost-
wijkstraat 3, NL-1391 EP Abcoude (NL). KUIKEN,
Thijs (NL/NL); Middenmolenlaan 149, NL-2807 EV
Gouda (NL). FOUCHIER, Ronaldus, Adrianus, Maria
(NL/NL); Essenburgsingel 44a, NL-3021 AR Rotterdam
(NL). OSTERHAUS, Albertus, Dominicus, Marcellus,
Erasmus (NL/NL); Dr. Brevestraat 16, NL-3981
CH Bunnik (NL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SARS

(57) Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian positive-
sense single stranded RNA virus (SARS) within the group of coronaviruses and components thereof.

WO 2004/089983 A2

Title: SARS

5

The invention relates to the field of virology, more in particular to a new coronavirus. In particular sequences encoding (parts of) viral proteins are provided. Further, the invention relates to diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease (atypical pneumonia), in particular of mammals, more in particular in humans. In another embodiment the invention relates to the use of interferon, preferably pegylated interferon for the prophylactic or therapeutic treatment of animals, preferably vertebrates, more preferably birds or mammals, especially human, apes or rodents, infected with a coronavirus, more specifically an animal, preferably human infected with a SARS associated coronavirus (SARS-CoV).

Recently, a new virus has caused a global health risk because of its pathogenic effects in man combined with a relatively easy droplet transmission. The virus first was seen in the Chinese province Guangdong, was spread to Hong Kong in February 2003, and within two months it has been able to spread to several countries all over the world where it has caused 78 deaths out of 2300 people infected (New Scientist Online News 13:25 02 April 2003). The virus has been named SARS (Severe Acute Respiratory Syndrome) virus and causes a respiratory illness (atypical pneumonia) in man. This illness usually begins with a fever, sometimes associated with chills or other symptoms, including headache, rash, diarrhea, a general feeling of discomfort (malaise) and body aches. Some people also experience mild respiratory syndromes at the outset.

After 2 to 7 days, SARS patients may develop a dry, nonproductive cough that might be accompanied or progress to the point where insufficient oxygen is getting to the blood, visible as shortness of breath. In 10% to 20% of the cases, patients will require mechanical ventilation, and eventually the disease can lead to the death of the patient. Hospital personnel, children, elderly and people having an underlying condition such as diabetes or heart disease, or a weakened immune system, form the

highest risk group. Co-infection with other pathogens seems to occur frequently, especially with opportunistic pathogenic microorganisms such as human metapneumovirus (hMPV), Chlamydia, etcetera.

The incubation time for the virus is typically 2-7 days and the disease is transmitted by people sick with SARS coughing or sneezing droplets in the air.

As for yet it is not known if there is a cure for the disease. Several antiviral therapies have been applied, but with various results.

Also, for being able to prevent spread of the disease, it is of great importance to be able to recognise the disease in an early stage. Only then sufficient measures can be taken to isolate patients and initiate quarantine precautions. At this moment there is not yet a diagnostic tool in place.

Thus, there is great need in developing diagnostic tools and therapies for this disease.

The invention provides the nucleotide sequence of an isolated essentially mammalian positive-sense single stranded RNA virus belonging to the Coronaviruses, which is the causative factor for SARS. From a phylogenetic analysis of the sequences of the virus (Fig. 1) it appears that the virus is an intermediate between the group formed by TGEV (transmissible gastroenteritis virus), PEDV (porcine epidemic diarrhoea virus) and 229E (human coronavirus 229E) at one side, the group formed by BoCo (bovine coronavirus) and MHV (murine hepatitis virus) at an other side, and the AIBV (avian infectious bronchitis virus) on yet another side. In general, bovine coronavirus seems to be the closest relative (at least for the viral replicase protein).

Although phylogenetic analyses provide a convenient method of identifying a virus as a SARS virus several other possibly more straightforward albeit somewhat more coarse methods for identifying said virus or viral proteins or nucleic acids from said virus are herein also provided. As a rule of thumb a SARS virus can be identified by the percentages of homology of the virus, proteins or nucleic acids to be identified in comparison with viral proteins or nucleic acids identified herein by sequence. It is generally known that virus species, especially RNA virus species, often constitute a quasi species wherein a cluster of said viruses displays heterogeneity among its members. Thus it is expected that each isolate may have a somewhat different percentage relationship with the sequences of the isolate as provided herein.

When one wishes to compare a virus isolate with the sequences as listed in figure 2, the invention provides an isolated essentially mammalian positive-sense single stranded RNA virus (SARS) belonging to the Coronaviruses and identifiable as phylogenetically corresponding thereto by determining a nucleic acid sequence of said virus and determining that said nucleic acid sequence has a percentage nucleic acid identity to the sequences as listed higher than the percentages identified herein for the nucleic acids as identified herein below in comparison with BoCo, AIPV and PEDV. Likewise, an isolated essentially mammalian positive-sense single stranded RNA virus (SARS) belonging to the Coronaviruses and identifiable as phylogenetically corresponding thereto by determining an amino acid sequence of said virus and determining that said amino acid sequence has a percentage amino acid homology to the sequences as listed which is essentially higher than the percentages provided herein in comparison with BoCo, AIPV and PEDV.

With the provision of the sequence information of this SARS virus, the invention provides diagnostic means and methods, prophylactic means and methods and therapeutic means and methods to be employed in the diagnosis, prevention and/or treatment of disease, in particular of respiratory disease (atypical pneumonia), in particular of mammals, more in particular in humans. In virology, it is most advisory that diagnosis, prophylaxis and/or treatment of a specific viral infection is performed with reagents that are most specific for said specific virus causing said infection. In this case this means that it is preferred that said diagnosis, prophylaxis and/or treatment of a SARS virus infection is performed with reagents that are most specific for SARS virus. This by no means however excludes the possibility that less specific, but sufficiently cross-reactive reagents are used instead, for example because they are more easily available and sufficiently address the task at hand. The invention for example provides a method for virologically diagnosing a SARS infection of an animal, in particular of a mammal, more in particular of a human being, comprising determining in a sample of said animal the presence of a viral isolate or component thereof by reacting said sample with a SARS specific nucleic acid or antibody according to the invention, and a method for serologically diagnosing a SARS infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against a SARS virus or component

thereof by reacting said sample with a SARS virus-specific proteinaceous molecule or fragment thereof or an antigen according to the invention.

The invention also provides a diagnostic kit for diagnosing a SARS infection comprising a SARS virus, a SARS virus-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody according to the invention, and preferably a means for detecting said SARS virus, SARS virus-specific nucleic acid, proteinaceous molecule or fragment thereof, antigen and/or an antibody, said means for example comprising an excitable group such as a fluorophore or enzymatic detection system used in the art (examples of suitable diagnostic kit format comprise IF, ELISA, neutralization assay, RT-PCR assay). To determine whether an as yet unidentified virus component or synthetic analogue thereof such as nucleic acid, proteinaceous molecule or fragment thereof can be identified as SARS-virus-specific, it suffices to analyse the nucleic acid or amino acid sequence of said component, for example for a stretch of said nucleic acid or amino acid, preferably of at least 10, more preferably at least 25, more preferably at least 40 nucleotides or amino acids (respectively), by sequence homology comparison with the provided SARS viral sequences and with known non-SARS viral sequences (BoCo is preferably used) using for example phylogenetic analyses as provided herein. Depending on the degree of relationship with said SARS or non-SARS viral sequences, the component or synthetic analogue can be identified.

The invention thus provides the nucleotide sequence of a novel etiological agent, an isolated essentially mammalian positive-sense single stranded RNA virus (herein also called SARS virus) belonging to the Coronaviridae family, and SARS virus-specific components or synthetic analogues thereof. Coronaviruses were first isolated from chickens in 1937, while the first human coronavirus was propagated *in vitro* by Tyrell and Bono in 1965. There are now about 13 species in this family, which infect cattle, pigs, rodents, cats, dogs, birds and man. Coronavirus particles are irregularly shaped, about 60-220 nm in diameter, with an outer envelope bearing distinctive, 'club-shaped' peplomers (about 20 nm long and 10 nm wide at the distal end). This 'crown-like' appearance give the family its name. The envelope carries two glycoproteins: S, the spike glycoprotein which is involved in cell fusion and is a major antigen, and M, the membrane glycoprotein, which is involved in budding and envelope formation. The genome is associated with a basic phosphoprotein,

designated N. The genome of coronaviruses, a single stranded positive-sense RNA strand, is typically 27-31 Kb long and contains a 5' methylated cap and a 3' poly-A tail, by which it can directly function as an mRNA in the infected cell. Initially the 5' ORF 1 (about 20 Kb) is translated to produce a viral polymerase, which then produces a full length negative sense strand. This is used as a template to produce mRNA as a 'nested set' of transcripts, all with identical 5' non-translated leader sequence of 72 nucleotides and coincident 3' polyadenylated ends. Each mRNA thus produced is monocistronic, the genes at the 5' end being translated from the longest mRNA and so on. These unusual cytoplasmic structures are produced not by splicing, but by the polymerase during transcription. Between each of the genes there is a repeated intergenic sequence – AACUAAAC – which interacts with the transcriptase plus cellular factors to splice the leader sequence onto the start of each ORF. In some coronaviruses there are about 8 ORFs, coding for the proteins mentioned above, but also for a haemagglutinin esterase (HE), and several other non-structural proteins. Newly isolated viruses are phylogenetically corresponding to and thus taxonomically corresponding to SARS virus when comprising a gene order and/or amino acid sequence and/or nucleotide sequence sufficiently similar to our prototypic SARS virus. The highest amino acid sequence homology, between SARS virus and any of the known other viruses of the same family to date (BoCo or Mouse Hepatitis Virus) is for parts of the polymerase protein 18-61% (the % homology, and the virus to which the homology is depend on the region of the polymerase that is examined), as can be deduced when comparing the sequences given in figure 2 with sequences of other viruses, in particular of BoCo and Mouse Hepatitis Virus. Individual proteins or whole virus isolates with, respectively, higher homology than these mentioned maximum values are considered phylogenetically corresponding and thus taxonomically corresponding to SARS virus, and generally will be encoded by a nucleic acid sequence structurally corresponding with a sequence as shown in figure 2. Herewith the invention provides a virus phylogenetically corresponding to the isolated virus of which the sequences are depicted in figure 2.

It should be noted that, similar to other viruses, a certain degree of variation can be expected to be found between SARS-viruses isolated from different sources. Also, the viral sequence of the SARS virus or an isolated SARS virus gene as provided herein for example shows less than 95%, preferably less than 90%, more preferably less than 80%, more preferably less than 70% and most preferably less

than 65% nucleotide sequence homology or less than 95%, preferably less than 90%, more preferably less than 80%, more preferably less than 70% and most preferably less than 65% amino acid sequence homology with the respective nucleotide or amino acid sequence of the bovine coronavirus or the murine hepatitis virus as for example can be found in Genbank (for example in accession number NC_002306 (BoCo) or NC_002645 (MHV)).

Sequence divergence of SARS strains around the world may be somewhat higher, in analogy with other coronaviruses.

A fair number of virus isolates have been isolated during the priority year of the present application, and it has been found that these viruses share the homology indicated above. The sequences of these viruses can be found in GenBank accession no. AY274119 (see fig. 10) or AY278741 or AY338175 or AY338174 or AY322199 or AY 322198 or AY322197 or AH013000 or AY322208 or AY322207 AY 322206 or AY322205 or AH012999 and and/or sequences depicted in <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Undef&id=227859&lvl=3&keep=1&srchmode=1&unlock>. Herewith the invention encompasses a virus phylogenetically corresponding to the isolated virus of which the sequences are depicted in figure 2 and/or for example the GenBank accession no. AY274119 or AY278741 or AY338175 or AY338174 or AY322199 or AY 322198 or AY322197 or AH013000 or AY322208 or AY322207 AY 322206 or AY322205 or AH012999 and and/or sequences depicted in <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Undef&id=227859&lvl=3&keep=1&srchmode=1&unlock>.

The term "nucleotide sequence homology" as used herein denotes the presence of homology between two (poly)nucleotides. Polynucleotides have "homologous" sequences if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence. Sequence comparison between two or more polynucleotides is generally performed by comparing portions of the two sequences over a comparison window to identify and compare local regions of sequence similarity. The comparison window is generally from about 20 to 200 contiguous nucleotides. The "percentage of sequence homology" for polynucleotides, such as 50, 60, 70, 80, 90, 95, 98, 99 or 100 percent sequence homology may be determined by comparing two optimally aligned sequences over a comparison window, wherein the

portion of the polynucleotide sequence in the comparison window may include additions or deletions (i.e. gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by: (a) determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions; (b) dividing the number of matched positions by the total number of positions in the window of comparison; and (c) multiplying the result by 100 to yield the percentage of sequence homology. Optimal alignment of sequences for comparison may be conducted by computerized implementations of known algorithms, or by inspection. Readily available sequence comparison and multiple sequence alignment algorithms are, respectively, the Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. 1990. J. Mol. Biol. 215:403; Altschul, S.F. et al. 1997. Nucleic Acid Res. 25:3389-3402) and ClustalW programs both available on the internet. Other suitable programs include GAP, BESTFIT and FASTA in the Wisconsin Genetics Software Package (Genetics Computer Group (GCG), Madison, WI, USA).

As used herein, "substantially complementary" means that two nucleic acid sequences have at least about 65%, preferably about 70%, more preferably about 80%, even more preferably 90%, and most preferably about 98%, sequence complementarity to each other. This means that the primers and probes must exhibit sufficient complementarity to their template and target nucleic acid, respectively, to hybridise under stringent conditions. Therefore, the primer sequences as disclosed in this specification need not reflect the exact sequence of the binding region on the template and degenerate primers can be used. A substantially complementary primer sequence is one that has sufficient sequence complementarity to the amplification template to result in primer binding and second-strand synthesis.

The term "hybrid" refers to a double-stranded nucleic acid molecule, or duplex, formed by hydrogen bonding between complementary nucleotides. The terms "hybridise" or "anneal" refer to the process by which single strands of nucleic acid sequences form double-helical segments through hydrogen bonding between complementary nucleotides.

The term "oligonucleotide" refers to a short sequence of nucleotide monomers (usually 6 to 100 nucleotides) joined by phosphorous linkages (e.g., phosphodiester, alkyl and aryl-phosphate, phosphorothioate), or non-phosphorous linkages (e.g., peptide, sulfamate and others). An oligonucleotide may contain modified nucleotides having

modified bases (e.g., 5-methyl cytosine) and modified sugar groups (e.g., 2'-O-methyl ribosyl, 2'-O-methoxyethyl ribosyl, 2'-fluoro ribosyl, 2'-amino ribosyl, and the like). Oligonucleotides may be naturally-occurring or synthetic molecules of double- and single-stranded DNA and double- and single-stranded RNA with circular, branched
5 or linear shapes and optionally including domains capable of forming stable secondary structures (e.g., stem-and-loop and loop-stem-loop structures).

The term "primer" as used herein refers to an oligonucleotide which is capable of annealing to the amplification target allowing a DNA polymerase to attach thereby serving as a point of initiation of DNA synthesis when placed under conditions in
10 which synthesis of primer extension product which is complementary to a nucleic acid strand is induced, i.e., in the presence of nucleotides and an agent for polymerization such as DNA polymerase and at a suitable temperature and pH. The (amplification) primer is preferably single stranded for maximum efficiency in amplification.

Preferably, the primer is an oligodeoxy ribonucleotide. The primer must be
15 sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization. The exact lengths of the primers will depend on many factors, including temperature and source of primer. A "pair of bi-directional primers" as used herein refers to one forward and one reverse primer as commonly used in the art of DNA amplification such as in PCR amplification.

20 The term "probe" refers to a single-stranded oligonucleotide sequence that will recognize and form a hydrogen-bonded duplex with a complementary sequence in a target nucleic acid sequence analyte or its cDNA derivative.

The terms "stringency" or "stringent hybridization conditions" refer to hybridization conditions that affect the stability of hybrids, e.g., temperature, salt concentration,
25 pH, formamide concentration and the like. These conditions are empirically optimised to maximize specific binding and minimize non-specific binding of primer or probe to its target nucleic acid sequence. The terms as used include reference to conditions under which a probe or primer will hybridise to its target sequence, to a detectably greater degree than other sequences (e.g. at least 2-fold over background). Stringent
30 conditions are sequence dependent and will be different in different circumstances.

Longer sequences hybridise specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target

sequence hybridises to a perfectly matched probe or primer. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na⁺ ion, typically about 0.01 to 1.0 M Na⁺ ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes or primers (e.g. 10 to 50 nucleotides) and at least about 60°C for long probes or primers (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringent conditions or "conditions of reduced stringency" include hybridization with a buffer solution of 30% formamide, 1 M NaCl, 1% SDS at 37°C and a wash in 2x SSC at 40°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1x SSC at 60°C. Hybridization procedures are well known in the art and are described in e.g. Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994.

The term "antibody" includes reference to antigen binding forms of antibodies (e. g., Fab, F(ab) 2). The term "antibody" frequently refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). However, while various antibody fragments can be defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments such as single chain Fv, chimeric antibodies (i. e., comprising constant and variable regions from different species), humanized antibodies (i. e., comprising a complementarity determining region (CDR) from a non-human source) and heteroconjugate antibodies (e. g., bispecific antibodies).

"Interferon" is a term generically comprehending a group of vertebrate glycoproteins and proteins which are known to have various biological activities, such as antiviral, antiproliferative, and immunomodulatory activity at least in the species of animal from which such substances are derived. Interferon refers to a class of small protein and glycoprotein cytokines (15–28 kD) produced by T cells, fibroblasts, and other cells in response to viral infection and other biological and synthetic stimuli. Interferons bind to specific receptors on cell membranes; their effects include inducing enzymes, suppressing cell proliferation, inhibiting viral proliferation, enhancing the phagocytic activity of macrophages, and augmenting the cytotoxic activity of T lymphocytes.

Interferons are divided into five major classes (alpha, beta, gamma, tau, and omega) and several subclasses (indicated by Arabic numerals and letters) on the basis of physicochemical properties, cells of origin, mode of induction, and antibody reactions.

5 In short, the invention provides an isolated essentially mammalian positive-sense single stranded RNA virus (SARS) belonging to the Coronaviruses and identifiable as phylogenetically corresponding thereto by determining a nucleic acid sequence of a suitable fragment of the genome of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using
10 100 bootstraps and 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate having the sequences as depicted in figure 2 than it is corresponding to a virus isolate of BoCo (bovine coronavirus, e.g. acc. no. NC_002306 in Genbank), MHV (murine hepatitis virus, e.g. acc. no. NC_002645), AIBV (avian infectious bronchitis virus, e.g. acc. no. NC_001451), PEDV (porcine epidemic
15 diarrhea virus), TGEV (transmissible gastroenteritis virus, e.g. acc. no. NC_003436) or 229E (human coronavirus 229E, e.g. acc. no. NC_003045). All the viral sequences with the GenBank accession numbers mentioned above are believed to be phylogenetically corresponding viruses to the virus of which the sequences are depicted in fig. 2.

20 Suitable nucleic acid genome fragments each useful for such phylogenetic tree analyses are for example any of the RAP-PCR fragments EMC-1 to -14 and RDG-1 as disclosed in figure 2, leading to the phylogenetic tree analysis as disclosed in figure 1.

A suitable open reading frame (ORF) comprises the ORF encoding the viral
25 polymerase (ORF 1a). When an overall amino acid identity of at least 60%, preferably of at least 70%, more preferably of at least 80%, more preferably of at least 90%, most preferably of at least 95% of the analysed polymerase with the polymerase having a sequence comprising the amino acid fragments EMC-1, EMC-2, EMC-3, EMC-4, EMC-5, EMC-13 and/or EMC-14 of figure 2 is found, the analysed virus isolate comprises a
30 SARS virus isolate according to the invention.

Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the N protein. When an overall amino acid identity of at least 60%, more preferably of at least 70%, more preferably of at least 80%, more preferably of at least 90%, most preferably of at least 95% of the analysed N-protein

with the N-protein encoded by a sequence comprising the sequence EMC-8 of figure 2 is found, the analysed virus isolate comprises a SARS isolate according to the invention.

Another suitable open reading frame (ORF) useful in phylogenetic analyses comprises the ORF encoding the spike protein S. When an overall amino acid identity of at least 60%, more preferably of at least 70%, more preferably of at least 80%, more preferably of at least 90%, most preferably of at least 95% of the analysed S-protein encoded by a sequence comprising the sequence of translation 2 of EMC7 and translation 1 of the RDG 1 sequence of the S-protein as depicted in figure 2 is found, the analysed virus isolate comprises a SARS virus isolate according to the invention. The S ORF of the SARS virus seems to be located adjacent to the ORF 1ab (coding for the viral polymerase), which would discriminate SARS viruses from the bovine coronavirus and the murine hepatitis virus, which have a so-called 2a gene and an HE-gene between the S protein and the viral polymerase.

15

The invention provides among others an isolated or recombinant nucleic acid or virus-specific functional fragment thereof obtainable from a virus according to the invention. The isolated or recombinant nucleic acids comprises the sequences as given in figure 2 or sequences of homologues which are able to hybridise with those under stringent conditions. In particular, the invention provides primers and/or probes suitable for identifying a SARS virus nucleic acid.

Furthermore, the invention provides a vector comprising a nucleic acid according to the invention. To begin with, vectors such as plasmid vectors containing (parts of) the genome of SARS virus, virus vectors containing (parts of) the genome of SARS (for example, but not limited thereto, vaccinia virus, retroviruses, baculovirus), or SARS virus containing (parts of) the genome of other virus or other pathogens are provided.

Also, the invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of SARS virus are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the SARS virus genome will be generated in prokaryotic cells for the expression of viral nucleic acids *in-vitro* or *in-vivo*. The latter vectors may contain other viral sequences for the generation of chimeric viruses or

30

chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

5 Infectious copies of SARS virus (being wild type, attenuated, replication-defective or chimeric) can be produced upon co-expression of the polymerase components according to the state-of-the-art technologies described above.

In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial SARS virus proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral
10 vectors) and may be useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses. For example, it can be envisaged that a SARS virus vector expressing one or more proteins of a human
15 metapneumovirus or a human metapneumovirus vector expressing one or more proteins of SARS virus will protect individuals vaccinated with such vector against both virus infections. Such a specific chimeric virus is particularly useful in the invention because it is suspected that co-infection of, for instance, human metapneumovirus frequently occurs in SARS virus infected patients. Attenuated and
20 replication-defective viruses may be of use for vaccination purposes with live vaccines as has been suggested for other viruses. Recently, Subbarao, K. *et al.*, J. Virol. **78**(7), 3572-3577, 2004) demonstrated that mice are protected as a result from a previous immunisation with whole viruses.

In a preferred embodiment, the invention provides a proteinaceous molecule or
25 coronavirus-specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from a virus according to the invention. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical
30 compositions such as sub-unit vaccines and inhibitory peptides. Particularly useful are the viral polymerase protein, the spike protein, the nucleocapsid or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments that are

identified for phylogenetic analyses, of course preferred are those that are within the preferred bounds and metes of ORFs useful in phylogenetic analyses, in particular for eliciting SARS virus specific antibodies, whether in vivo (e.g. for protective purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

Also provided herein are antibodies, be it natural polyclonal or monoclonal, or synthetic (e.g. (phage) library-derived binding molecules) antibodies that specifically react with an antigen comprising a proteinaceous molecule or SARS virus-specific functional fragment thereof according to the invention. A person skilled in the art will be able to develop (monoclonal) antibodies using isolated virus material and/or recombinantly expressed viral proteins. Sui et al. (Proc. Natl. Acad. Sci. 101(8), 2536-2541, 2004) have transiently expressed fragments of the spike protein and found several antibodies through phage display methods. One of these antibodies was shown to be directed to the N-terminal 261-672 amino acids of the S (spike) protein (which would be corresponding to the sequence of translation 2 of EMC7 and translation 1 of the RDG 1 sequence of the S-protein as depicted in figure 2) and this antibody was also demonstrated to have neutralising properties, indicating that it may be a candidate for successful vaccines. Also Subbarao et al. (supra) showed that serum from mice that had been infected with SARS virus was able to block infectivity of 100 TCID₅₀ of SARS virus in Vero cell monolayers, due to the presence of neutralising antibodies.

Such antibodies are also useful in a method for identifying a viral isolate as a SARS virus comprising reacting said viral isolate or a component thereof with an antibody as provided herein. This can for example be achieved by using purified or non-purified SARS virus or parts thereof (proteins, peptides) using ELISA, RIA, FACS or similar formats of antigen detection assays (Current Protocols in Immunology). Alternatively, infected cells or cell cultures may be used to identify viral antigens using classical immunofluorescence or immunohistochemical techniques. Specifically useful in this respect are antibodies raised against SARS virus proteins which are encoded by a nucleotide sequence comprising one or more of the fragments disclosed in figure 2.

Other methods for identifying a viral isolate as a SARS virus comprise reacting said viral isolate or a component thereof with a virus specific nucleic acid according to the invention.

In this way the invention provides a viral isolate identifiable with a method according to the invention as a mammalian virus taxonomically corresponding to a positive-sense single stranded RNA virus identifiable as likely belonging to the SARS virus genus within the family of Coronaviruses.

The method is useful in a method for virologically diagnosing a SARS virus infection of a mammal, said method for example comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid or an antibody according to the invention.

Methods of the invention can in principle be performed by using any nucleic acid amplification method, such as the Polymerase Chain Reaction (PCR; Mullis 1987, U.S. Pat. No. 4,683,195, 4,683,202, en 4,800,159) or by using amplification reactions such as Ligase Chain Reaction (LCR; Barany 1991, Proc. Natl. Acad. Sci. USA 88:189-193; EP Appl. No., 320,308), Self-Sustained Sequence Replication (3SR; Guatelli et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), Strand Displacement Amplification (SDA; U.S. Pat. Nos. 5,270,184, en 5,455,166), Transcriptional Amplification System (TAS; Kwok et al., Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al., 1988, BioTechnology 6:1197), Rolling Circle Amplification (RCA; U.S. Pat. No. 5,871,921), Nucleic Acid Sequence Based Amplification (NASBA), Cleavase Fragment Length Polymorphism (U.S. Pat. No. 5,719,028), Isothermal and Chimeric Primer-initiated Amplification of Nucleic Acid (ICAN), Ramification-extension Amplification Method (RAM; U.S. Pat. Nos. 5,719,028 and 5,942,391) or other suitable methods for amplification of nucleic acids.

In order to amplify a nucleic acid with a small number of mismatches to one or more of the amplification primers, an amplification reaction may be performed under conditions of reduced stringency (e.g. a PCR amplification using an annealing temperature of 38°C, or the presence of 3.5 mM MgCl₂). The person skilled in the art will be able to select conditions of suitable stringency.

The primers herein are selected to be "substantially" complementary (i.e. at least 65%, more preferably at least 80% perfectly complementary) to their target regions present on the different strands of each specific sequence to be amplified. It is possible to use primer sequences containing e.g. inositol residues or ambiguous bases

or even primers that contain one or more mismatches when compared to the target sequence. In general, sequences that exhibit at least 65%, more preferably at least 80% homology with the target DNA or RNA oligonucleotide sequences, are considered suitable for use in a method of the present invention. Sequence mismatches are also not critical when using low stringency hybridization conditions.

The detection of the amplification products can in principle be accomplished by any suitable method known in the art. The detection fragments may be directly stained or labelled with radioactive labels, antibodies, luminescent dyes, fluorescent dyes, or enzyme reagents. Direct DNA stains include for example intercalating dyes such as acridine orange, ethidium bromide, ethidium monoazide or Hoechst dyes.

Alternatively, the DNA or RNA fragments may be detected by incorporation of labelled dNTP bases into the synthesized fragments. Detection labels which may be associated with nucleotide bases include e.g. fluorescein, cyanine dye or BrdUrd.

When using a probe-based detection system, a suitable detection procedure for use in the present invention may for example comprise an enzyme immunoassay (EIA) format (Jacobs et al., 1997, *J. Clin. Microbiol.* 35, 791-795). For performing a detection by manner of the EIA procedure, either the forward or the reverse primer used in the amplification reaction may comprise a capturing group, such as a biotin group for immobilization of target DNA PCR amplicons on e.g. a streptavidin coated microtiter plate wells for subsequent EIA detection of target DNA -amplicons (see below). The skilled person will understand that other groups for immobilization of target DNA PCR amplicons in an EIA format may be employed.

Probes useful for the detection of the target DNA as disclosed herein preferably bind only to at least a part of the DNA sequence region as amplified by the DNA amplification procedure. Those of skill in the art can prepare suitable probes for detection based on the nucleotide sequence of the target DNA without undue experimentation as set out herein. Also the complementary nucleotide sequences, whether DNA or RNA or chemically synthesized analogs, of the target DNA may suitably be used as type-specific detection probes in a method of the invention, provided that such a complementary strand is amplified in the amplification reaction employed.

Suitable detection procedures for use herein may for example comprise immobilization of the amplicons and probing the DNA sequences thereof by e.g. southern blotting. Other formats may comprise an EIA format as described above. To

facilitate the detection of binding, the specific amplicon detection probes may comprise a label moiety such as a fluorophore, a chromophore, an enzyme or a radio-label, so as to facilitate monitoring of binding of the probes to the reaction product of the amplification reaction. Such labels are well-known to those skilled in the art and include, for example, fluorescein isothiocyanate (FITC), β -galactosidase, horseradish peroxidase, streptavidin, biotin, digoxigenin, ^{35}S or ^{125}I . Other examples will be apparent to those skilled in the art.

Detection may also be performed by a so called reverse line blot (RLB) assay, such as for instance described by Van den Brule et al. (2002, J. Clin. Microbiol. 40, 779-787). For this purpose RLB probes are preferably synthesized with a 5' amino group for subsequent immobilization on e.g. carboxyl-coated nylon membranes. The advantage of an RLB format is the ease of the system and its speed, thus allowing for high throughput sample processing.

The use of nucleic acid probes for the detection of RNA or DNA fragments is well known in the art. Mostly these procedure comprise the hybridization of the target nucleic acid with the probe followed by post-hybridization washings. Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For nucleic acid hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl, Anal. Biochem., 138: 267-284 (1984): $T_m = 81.5^\circ\text{C} + 16.6 (\log M) + 0.41 (\% \text{ GC}) - 0.61 (\% \text{ form}) - 500/L$; where M is the molarity of monovalent cations, $\% \text{ GC}$ is the percentage of guanosine and cytosine nucleotides in the nucleic acid, $\% \text{ form}$ is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1°C for each 1 % of mismatching; thus, the hybridization and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with $> 90\%$ identity are sought, the T_m can be decreased 10°C . Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at $1, 2, 3$, or 4°C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at $6, 7, 8, 9$, or 10°C lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization

and/or wash at 11,12,13,14,15, or 20 °C lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m, those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45 °C (aqueous solution) or 32 °C (formamide solution) it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes, Part I, Chapter 2" Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York (1993); and Current Protocols in Molecular Biology, Chapter 2, Ausubel, et al., Eds., Greene Publishing and Wiley-Interscience, New York (1995).

In another aspect, the invention provides oligonucleotide probes for the generic detection of target RNA or DNA. The detection probes herein are selected to be "substantially" complementary to one of the strands of the double stranded nucleic acids generated by an amplification reaction of the invention. Preferably the probes are substantially complementary to the immobilizable, e.g. biotin labelled, antisense strands of the amplicons generated from the target RNA or DNA.

It is allowable for detection probes of the present invention to contain one or more mismatches to their target sequence. In general, sequences that exhibit at least 65%, more preferably at least 80% homology with the target oligonucleotide sequences are considered suitable for use in a method of the present invention. Antibodies, both monoclonal and polyclonal, can also be used for detection purpose in the present invention, for example, in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. In addition, the monoclonal antibodies in these immunoassays can be detectably labeled in various ways. A variety of immunoassay formats may be used to select antibodies specifically reactive with a particular protein (or other analyte). For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions that can be used to determine selective binding. Examples of types of immunoassays that can utilize antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such

immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay. Detection of the antigens using the antibodies of the invention can be done utilizing immunoassays that are run in either the forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

Antibodies can be bound to many different carriers and used to detect the presence of the target molecules. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or will be able to ascertain such using routine experimentation.

The invention also provides a method for serologically diagnosing a SARS virus infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against a SARS virus or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof or an antigen according to the invention

Methods and means provided herein are particularly useful in a diagnostic kit for diagnosing a SARS virus infection, be it by virological or serological diagnosis. Such kits or assays may for example comprise a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention.

Use of a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention is also provided for the production of a pharmaceutical composition, for example for the treatment or prevention of SARS virus infections and/or for the treatment or prevention of atypical pneumonia, in particular in humans. Preferably a peptide comprising part of the amino acid sequence of the spike protein as depicted in translation 2 with the sequence EMC7 and translation 1 of the RDG seq of figure 2, is used for the preparation of a therapeutic or prophylactic peptide. Also preferably, a protein comprising the amino acid sequence of the spike protein as depicted in translation 2 with the sequence EMC7 translation 1 of the RDG seq of figure 2, is used for the preparation of a sub-unit vaccine. Furthermore, the nucleocapsid of Coronaviruses, as

depicted in the translation of EMC8, in figure 2, is known to be particularly useful for eliciting cell-mediated immunity against Coronaviruses and can be used for the preparation of a sub-unit vaccine.

5 Attenuation of the virus can be achieved by established methods developed for this purpose, including but not limited to the use of related viruses of other species, serial passages through laboratory animals or/and tissue/cell cultures, serial passages through cell cultures at temperatures below 37°C (cold-adaptation), site directed mutagenesis of molecular clones and exchange of genes or gene fragments between related viruses.

10 As is shown by Sui et al. (*supra*) humanised neutralising antibodies have been prepared which have shown to be reactive with the N-terminal 261-672 amino acids of the spike protein of the SARS virus.

A pharmaceutical composition comprising a virus, a nucleic acid, a proteinaceous molecule or fragment thereof, an antigen and/or an antibody according to the invention can for example be used in a method for the treatment or prevention of a SARS virus infection and/or a respiratory illness comprising providing an individual with a pharmaceutical composition according to the invention. This is most useful when said individual comprises a human. Antibodies against SARS virus proteins, especially against the spike protein of SARS virus, preferably against the amino acid sequence as depicted in translation 2 of EMC7 and translation 1 of the RDG seq in figure 2, are also useful for prophylactic or therapeutic purposes, as passive vaccines. It is known from other coronaviruses that the spike protein is a very strong antigen and that antibodies against spike protein can be used in prophylactic and therapeutic vaccination.

25 The invention also provides method to obtain an antiviral agent useful in the treatment of atypical pneumonia comprising establishing a cell culture or experimental animal comprising a virus according to the invention, treating said culture or animal with a candidate antiviral agent, and determining the effect of said agent on said virus or its infection of said culture or animal. An example of such an antiviral agent comprises a SARS virus-neutralising antibody, or functional component thereof, as provided herein, but antiviral agents of other nature are obtained as well. The invention also provides use of an antiviral agent according to the invention for the preparation of a pharmaceutical composition, in particular for the preparation of a pharmaceutical composition for the treatment of atypical

pneumonia, specifically when caused by a SARS virus infection, and provides a pharmaceutical composition comprising an antiviral agent according to the invention, useful in a method for the treatment or prevention of a SARS virus infection or atypical pneumonia, said method comprising providing an individual with such a pharmaceutical composition.

Specifically the invention provides a pharmaceutical composition comprising interferon, especially pegylated interferon.

In general all interferon forms would be useful in the present invention, since it is known that all the interferon forms have at least some activity in alleviating (symptoms of) viral infection. However, it is to be understood that preferentially the interferon is used which is derived from the host which is infected with, or which runs the risk of being infected with the virus. Further, most preferred is the use of interferon-alpha, and especially - for coronavirus infections that affect humans, like SARS - human interferon-alpha. Alpha interferon is a natural protein produced by the human body in response to infection. It is also known as interferon alpha-2b. The type I interferon alpha family consists of small proteins that have clinically important anti-infective and anti-tumor activity. It is understood that alpha interferon may be administered alone or in combination with beta interferon or gamma interferon.

Genetic engineering techniques have allowed several companies to mass-produce alpha interferon, which is known as recombinant human alpha interferon, or by abbreviations such as rhIFN or rIFN-alpha. This is marketed under tradenames such as Viraferon (made by Schering-Plough), Roferon-A (by Roche) and Wellferon (by Glaxo SmithKline). Interferon-alpha N3, or Alferon N, is another form of interferon alpha, derived from human leukocytes and containing multiple species of interferon-alpha.

A drawback to the use of interferon-alpha as discussed previously, is the short serum half-life and rapid clearance of the interferon alpha protein. However, it has been shown that the attachment of molecules of polyethylene glycol (PEG) to the interferon, creates a barrier that shields the interferon alfa-2a molecule from being rapidly degraded by proteases in the body and maintains its ability to consistently suppress the target virus over a longer dosage period.

As already discussed above pegylation of proteins such as inteferon is used to prevent rapid removal from the bloodstream and eventually rapid breakdown of the

drug. A prolongation of the serum half-life of more than a factor two has been demonstrated (Shannon A. Marshall, Drug Discovery Today Volume 8, Issue 5, March 2003, Pages 212-221). Pegylated IFN alfa-2b has a prolonged serum half-life (40 hours) relative to standard IFN alfa-2b (7-9 hours). The greater size of pegylated IFN alfa-2a acts to reduce glomerular filtration, markedly prolonging its serum half-life (72-96 hours) compared with standard IFN alfa-2a (6-9 hours) (Bruce A. Luxon MD Clinical Therapeutics, Volume 24, Issue 9, September 2002, Pages 1363-1383).

Pegylation of proteins is a standard technique available to a person skilled in the art, and standard pegylated interferons are available commercially from Roche (PEGASYS® (interferon alfa 2a) and Schering-Plough (PEG-Intron A) or in development like PEG-Alfacon, the PEGylated version of Infergen(R) (Interferon alfacon-1) a bio-engineered type I interferon alfa.

Schering-Plough has developed a semi-synthetic form of Intron® A by attaching a 12-kDa mono-methoxy polyethylene glycol to the protein (PEG Intron) which fulfils the requirements of a long-acting interferon alpha protein while providing significant clinical benefits. Pegylation decreases the specific activity of the interferon alpha-2b protein, whilst the potency of PEG Intron, independent of protein concentration, is comparable to the Intron® A standard at both the molecular and cellular level. PEG Intron has enhanced pharmacokinetic profile in both animal and human studies [see Yu-Sen Wang et al., 2002: Advanced Drug Delivery Reviews, Volume 54, Issue 4, 17, Pages 547-570]. In PEGASYS, a 40 kilodalton branched, mobile PEG is covalently bound to the interferon alfa-2a molecule and provides a selectively protective barrier without significantly reducing binding site receptivity.

It is understood that pharmacokinetic behaviour of a pegylated molecule depends on the size of the PEG and the structure of the link between the PEG moiety and the protein (Shannon A. Marshall, Drug Discovery Today Volume 8, Issue 5, March 2003, Pages 212-221). It is known that interferons with smaller PEGs are degraded quickly, requiring more frequent dosing. Thus interferons with larger PEGs are preferred.

Thus the present invention encompasses all types of pegylated interferons or future interferons with yet undisclosed molecule attachments which provide a selectively protective barrier, to shield the interferon from being degraded, without significantly reducing binding site receptivity. Also combinations of different interferons are encompassed in the invention

One of the most preferred embodiments of the present invention is the use of interferon as a prophylactic treatment for the prevention of coronavirus infection. Subjecting apes to a prophylactic or therapeutic treatment either before or during infection with the coronavirus has a good and useful predictionary value for
5 application of such a prophylaxis or therapy in human subjects.

As is shown in the experimental section administration of interferon before infestation with virus particles greatly delays infection and the effects after infection. It should be understood that the virus challenge given to the test animals is a high
10 dose, which will not or hardly ever occur in 'natural' infections. It is understood that viral challenge under 'natural' circumstances would equate with a challenge of about 10-105 TCID₅₀ with a concentration which is much less than that used in the experiment of the invention. Further, the viral challenge in the experiment was for the largest part applied intra-tracheal, i.e. at the place where the virus exerts its
15 main infective activity. Normally, a virus will be encountered in the air that is breathed and this air will firstly pass the nose and/or oral cavity, where it will have a large chance of being filtered out (and stopped) by the epithelium and mucosa of the mouth and/or the nose. Anyhow, the fact that even at the extremely high dose used in our experiments we have been able to show effect of interferon indicates that the
20 effect will even be more pronounced at infective viral doses which are normally encountered. It is therefore believed that prophylactic administration will give a durable and strong protection against infection with coronaviruses.

This is especially important in relation to viruses which are highly infective and/or which have an airborne mode of transmission, such as, for instance, the SARS
25 virus. A prophylactic treatment would be especially welcome for people who run a risk of being infected, such as, in the case of SARS virus, hospital personnel, children, elderly and people having an underlying condition such as diabetes or heart disease, or a weakened immune system.

It remains possible that SARS-CoV infection might be asymptomatic in some
30 people, or cause nonrespiratory symptoms in others. There is insufficient evidence to exclude the possibility that asymptomatic, or atypical, infected people can transmit the disease. Thus a prophylactic treatment for the prevention of coronavirus infection, like SARS-CoV is indeed essential.

However, our data also show that interferon is also applicable for therapy of coronaviruses, i.e. at the time when virus infection is already established. Our in vivo data show that pathologic effects are at least delayed upon administration of interferon.

- 5 Interferon of human and murine origins has been quantified in the art in terms of International Units ("IU"). As used herein, a "unit" of interferon (to be distinguished from "IU") shall mean the reciprocal of a dilution of interferon-containing material that, as determined by assay, inhibits one-half the number of plaques of a challenge virus, the challenge virus being the vesicular stomatitis virus ("VSV"). So quantified a "unit" of interferon is routinely found to be about one-tenth
10 the quantity of interferon represented by one "IU." Alternatively, interferon can be quantitated in $\mu\text{g/kg}$ of body weight.

- Interferon is given in doses ranging from $1\mu\text{g/kg}$ to $3\mu\text{g/kg}$. When the interferon is pegylated doses can be delivered less frequently. Treatment of
15 coronavirus disease in accordance with the present invention comprises administering pegylated interferon at a dosage of $0.01\text{-}6\mu\text{g/kg}$ per day in a dosage form adapted to promote contact of said dosage of interferon with the oral and pharyngeal mucosa of said animal. Preferably, the dosage of interferon is from $0.1\text{-}4\mu\text{g/kg}$ per day, more preferably $0.3\text{-}3\mu\text{g/kg}$ per day.

- 20 Interferon may be administered by any available means, including but not limited to, oral, intravenous, intramuscular, pulmonary and nasal routes, and wherein said composition is present as a solution, a suspension or an aerosol spray, especially of fine particles.

- It is critical that the pegylated interferon be administered in a dosage form
25 adapted to assure maximum contact of the interferon in said dosage form with the oral and pharyngeal mucosa of the human or animal, undergoing treatment. Contact of interferon with the mucosa can be enhanced by maximizing residence time of the treatment solution in the oral or pharyngeal cavity. Thus, best results seem to be achieved in human patients when the patient is requested to hold said solution of
30 interferon in the mouth for a period of time. Contact of interferon with the oral and pharyngeal mucosa and thereafter with the lymphatic system of the treated human or animal avian, rodent is unquestionably the most efficient method administering immunotherapeutic amounts of pegylated interferon.

For example interferon can be administered in either a liquid (solution) or solid dosage form. Thus interferon can be administered dissolved in a buffered aqueous solution typically containing a stabilizing amount (1-5% by weight) of blood serums. Exemplary of a buffered solution suitable as a carrier of interferon
5 administered in accordance with this invention is phosphate buffered saline prepared by standard techniques.

It is also contemplated by the present invention to provide interferon in a solid dosage form such as a lozenge adapted to be dissolved upon contact with saliva in the mouth with or without the assistance of chewing. Such a unitary dosage form is
10 formulated to release about 1 to about 1500 IU of interferon upon dissolution in the mouth for contact with the oral and pharyngeal mucosa. Thus a unitary dosage form of interferon in accordance with this invention can be prepared by art-recognized techniques for forming compressed tablets such as chewable vitamins. Similarly, interferon can be incorporated into starch-based gel formulations to form a lozenge
15 which will dissolve and release interferon for contact with the oral mucosa when held in the mouth. Solid unitary dosage forms of interferon for use in accordance with the present invention can be prepared utilizing art recognized dosage formulation techniques. The pH of such formulations can range from about 4 to about 8.5. Of course, in processing to such unitary dosage forms one should avoid heating a pre-
20 dosage form formulation, after addition of interferon, above about 50°C. Exemplary of a solid dosage form for animal use is a molasses block containing effective amounts of interferon.

Alternatively the interferon can be formulated into flavoured or unflavoured solutions or syrups using a buffered aqueous solution of interferon as a base with added caloric
25 or non-caloric sweeteners, flavour oils and pharmaceutically acceptable surfactant/dispersants.

Also contemplated are methods of gene therapy capable of causing expression of interferon in respiratory or gastric cells for prevention of a coronaviral infection.

Of course, the clinical use of any medicament of the present invention is a
30 clinical decision to be made by the clinician and the exact course of such treatment is left to the clinician's sound discretion, with all such courses of treatment deemed within the bounds of the present invention.

Another preferred embodiment is administration of interferon together with another treatment which is directed to prevent or treat infection with coronaviruses.

Such other treatment can for instance be a vaccine, antibody and/or anti-viral agent selected from the group consisting of whole inactivated virus vaccines, attenuated vaccines, sub-unit vaccines, recombinant vaccines, antibody for passive immunization, nucleoside analogs such as ribavirin, RNA-dependent RNA
5 polymerase inhibitors and protease inhibitors.

Use of interferon together with administration of a vaccine will boost the effects of the vaccine. First of all, there is the combination of treatments that will add up to a better effect. However, co-administration of interferon with a vaccine will also enable the immune response to vaccination to have more effect. Normally the
10 immune response is slow and it takes a few days to come to a high enough titer of antibodies to be able to effectively combat virus particles. When no interferon is co-administered the virus would have had the chance to multiply to enormous amounts, which cannot be overcome by the immune response. With interferon, however, the amounts of the virus will remain absent or low and any infective virus outburst (if
15 any at all) can easily be handled by the immune system.

Treatment to prevent and/or treat infection with coronaviruses can also comprise combination treatments with other antiviral compounds, such as, for instance, nucleoside-based compounds such as ribavirin (e.g. Rebetol® (ribavirin, USP). These compounds act through interfering with the viral replication by
20 presenting nucleosides which are built in during viral replication, but which either prevent formation of viral proteins or which do not yield functional proteins. Co-administration of interferon will even more slow down viral replication. Combinations of ribavirin and forms of interferon can help to reduce viral load.

Another disease condition responding to treatment in accordance with the
25 present invention is neoplastic disease. Thus, the administration of interferon in accordance with the above description can, alone or in combination with other drugs or therapy, help effect remission of cancers such as malignant lymphoma, melanoma, mesothelioma, Burkitt lymphoma and nasopharyngeal carcinoma and other neoplastic diseases, especially those of known or suspected viral etiology and diseases
30 such as Hodgkin's Disease and leukemia.

Other disease conditions responding to treatment in accordance with the present invention are infectious diseases of coronaviral origin in human, avian, porcine, canine and feline species. Human coronaviruses are coronavirus 229E and the newly discovered coronavirus HCoV-NL (see European patent application 03078772.5.

Several other coronaviruses can cause fatal systemic diseases in animals, including feline infectious peritonitis virus (FIPV), hemagglutinating encephalomyelitis virus (HEV) of swine, and some strains of avian infectious bronchitis virus (IBV) and mouse hepatitis virus (MHV). These coronaviruses can replicate in liver, lung, kidney, gut, spleen, brain, spinal cord, retina, and other tissues. Immunopathology plays a role in tissue damage in MHV and FIPV, and cytokines are responsible for some signs of disease. Significantly, in cats with persistent, inapparent infection with feline enterotropic coronavirus, virulent virus mutants can arise and cause fatal infectious peritonitis, a systemic disease.

10

The invention also comprises an animal model usable for testing of prophylactic and/or therapeutic methods and/or preparations. It has appeared that apes can be infected with the SARS virus, thereby showing clinical symptoms, and more importantly, similar tissue morphology as found in humans suffering from atypical pneumonia caused by the SARS virus. Subjecting apes to a prophylactic or therapeutic treatment either before or during infection with the virus will have a good and useful predictionary value for application of such a prophylaxis or therapy in human subjects.

15

The invention is further explained in the Examples without limiting it thereto.

Figure legends

Fig. 1: Phylogenetic relationship for the nucleotide sequences of isolate HK39849 with its closest relatives genetically. Phylogenetic trees were generated by maximum likelihood analyses using 100 bootstraps and 3 jumbles. The scale representing the number of nucleotide changes is shown for each tree.

Fig. 2: Nucleotide sequences from 13 clones of parts of the SARS virus. Also included are the putative polypeptide sequences of polypeptides and alignments of the putative polypeptides with that of another member of the Coronaviridae family, where possible.

Fig. 3: Schematic map of the SARS virus genome, indicating the position of the nucleotide sequences of figure 2 relative to the genome and a putative indication of the open reading frames of the genome based on analogy with other coronaviruses. The gene structure for the region between the Spike and Nucleocapsid is uncertain. EMC1-EMC14 and RDG 1: sequences as provided in figure 2. CDC and BIN1-2: sequences were provided through personal communication from the CDC (Dr. W. Bellini, Centers for Disease Control & Prevention, National Centers for Infectious Diseases, 1600 Clifton Road, Atlanta GA 30333, USA) and BNI (Dr. C. Drosten and Prof. Dr. H. Schmitz, Bernard Nocht Institute, Bernard-Nocht Str. 74, D-20359 Hamburg, Germany), respectively.

Fig. 4: Amino acid comparison of the N-terminus of the S-protein of the SARS virus and closely related coronaviruses. HCV OC43 = human coronavirus isolate OC43; MHV A59 = murine hepatitis virus isolate A59, BCV = bovine corona virus.

Fig. 5: Negative contrast EM photograph of SARS virus obtained from concentrated supernatant of infected cell cultures.

Fig. 6: Infection with SARS-coronavirus causes pulmonary and renal lesions in cynomolgus macaques. Formalin-fixed, paraffin-embedded tissues were stained with haematoxylin and eosin and examined by light microscopy. There is diffuse alveolar damage of the lung (a), and the alveolar lumina (b) are flooded with highly

proteinaceous exudate admixed with inflammatory cells and cellular debris. In the lumen of a bronchiole (c) and in the surrounding lung parenchyma are several multinucleated syncytial cells (arrowheads). The renal collecting tubules (d) contain similar multinucleated syncytial cells. Original magnifications: a x 12.5; b x 50; c x 100; d x 250.

Fig 7: Infection of domestic cats and ferrets with SCV. Cats (A, n=6) and ferrets (B, n=6) were infected with 10^6 TCID₅₀ via the respiratory route and secretion of SCV in pharyngeal swabs was quantified by real time PCR. Four animals per group were euthanised at day 4 while the other two were analysed till day 28. SCV secretion in non-infected cats (C, n=2) and non-infected ferrets (D, n=2) exposed to SCV infected cats and ferrets, respectively. Real time PCR results are shown relative to a titrated SCV standard and shown as TCID₅₀/ml (N.D. not done).

Fig. 8: Detection of SCV in postmortem tissues of experimentally SCV infected cats and ferrets

Fig. 9: Effect of pegylated IFN- α on SARS Coronavirus (SCV) replication in macaques. SCV detection in pharyngeal swabs (days 0, 2 and 4 after infection, closed bars) and lungs (day 4, open bars) taken from cynomolgus monkeys treated with PBS (A), PEG-Intron at days -3, -1, +1 and +3 (B and C) and PEG-Intron at days +1 and +3 (D) after SCV infection. Individual macaques are shown (n=2 per group). Virus isolation (VI) results are indicated in the lower part of the panel whereas real time PCR results are shown in the upper part of the panels (n.a., not available).

Fig. 10 Nucleotide sequence of SARS Corona virus Genbank accession nr. AY274119

Fig. 11 Antiviral activity of pegylated IFN- α against SCV in vitro and its biological activity in cynomolgus macaques. (a) Effect of pegylated IFN- α against SCV infection in vitro. Similar results were obtained in 3 separate experiments. (b) Pharmacokinetic analysis of pegylated IFN- α in macaques treated with PBS (control group; open squares, n = 4) or pegylated IFN- α (prophylactic group; closed squares, n = 4) at days -3 and -1. (c) Induction of neopterin in macaques treated with PBS

(control group; open squares, $n = 4$) or pegylated IFN- α (prophylactic group; closed squares, $n = 4$) at days -3 and -1. Data are expressed as mean \pm s.d.; **, $P < 0.01$ versus control.

- 5 Fig. 12 Effect of pegylated IFN- α on SCV excretion in cynomolgus macaques. SCV detection in pharyngeal swabs taken at 0, 2, or 4 d.p.i. from macaques treated with PBS (control group, $n = 4$), pegylated IFN- α prophylactically ($n = 6$) or post-exposure ($n = 4$). Data are expressed as mean \pm s.d.; *, $P < 0.05$ versus control group at 2 d.p.i., **, $P < 0.01$ versus control group at 2 d.p.i..

10

Fig. 13 Effect of pegylated IFN- α on SCV replication, viral antigen expression and histological lesions in the lungs of SCV-infected cynomolgus macaques. (a) SCV titration of lung homogenates. (b) Immunohistochemical detection of SCV-infected cells in lung sections. (c) Histopathological score of lung sections. SCV-infected

15 macaques were treated with pegylated IFN- α prophylactically ($n = 4$) or post-exposure ($n = 4$), or treated with PBS (control group, $n = 4$). Data are expressed as mean \pm s.d.; *, $P < 0.05$ versus control group; **, $P < 0.01$ versus control group.

Examples

Example 1. Virus isolation and characterisation

Isolation

5 Isolate HK39849 was isolated from a hospitalised SARS patient by throat swab and inoculated into a culture of Vero-E6 cells. A sample of the supernatant from these infected cells provided by Dr. M. Peiris (Queen Mary Hospital Faculty of Medicine, Hong Kong University, Honk Kong) was used to inoculate VERO-118 cells and cell culture supernatant from these cells was aliquoted and frozen after one
10 passage.

We isolated RNA from the virus-containing cell culture supernatant and subjected it to RNA arbitrarily primed PCR (RAP-PCR) essentially as described by Welsh & McClelland (NAR 18:7213; PNAS USA 90:10710, 1993). Virus in the culture supernatants was purified on continuous 20-60% sucrose gradients. The gradient
15 fractions were inspected for virus-like particles by EM, and RNA was isolated from the fraction containing , in which the most nucleocapsids were observed. Equivalent amounts of RNA isolated from virus fractions were used for RAP-PCR, after which samples were run side by side on a 3% NuSieve agarose gel. Differentially displayed bands ranging in size from 200-1500 base pairs specific for the unidentified virus
20 were subsequently purified from the gel, cloned in plasmid pCR2.1 (Invitrogen) and sequenced with vector-specific primers. When we used these sequences to search for homologies against sequences in the Genbank database using the BLAST software (www.ncbi.nlm.nih.gov/BLAST/) which yielded resemblance to virus sequences of the coronaviruses displayed in the phylogenetic tree of figure 1.

25 Eight of these fragments (EMC 1-6, 13 and 14) were located in the ORF coding for the viral polymerase (ORF 1ab), one (EMC-7) spanned the 3' end of ORF1ab and reached into the 5' end of spike protein region; EMC-10 overlapped the 3' end of EMC-7 and therefore also codes part of the S protein region and EMC 9 encodes a region downstream of EMC-10; by use of primers to sequences within EMC10 and EMC9
30 (see below), the region between these two sequences was amplified by PCR and sequenced. The full contiguous region has been incorporated into EMC7 in figure 2; a further sequence (RDG1 in figure 2) encodes the 3' end of the Spike protein. A further sequence (EMC8) spanned part of the Nucleocapsid coding sequence. The remaining three sequences (EMC9, 11 and 12) have in the meantime been found to be regions of

the orf 1ab/replicase, where emc 9 is incorporated in emc 11. This has not yet been reflected in figure 3.

Phylogeny

5 BLAST searches using nucleotide sequences obtained from the unidentified virus isolate revealed homologies primarily with members of the Coronaviridae. As an indication for the relation between the newly identified virus isolate and other coronaviruses a phylogenetic tree was constructed based on the sequence information obtained (figure 1).

10

Materials and Methods

Specimen collection

Virus was collected from SARS patients using throat swabs and from
15 experimentally infected monkeys (throat and nasal swabs, serum, plasma and faeces)

Virus isolation and culture

Throat swabs were dipped into a culture of Vero-E6 cells and incubated for 1-4 days. Cell culture supernatant was clarified by centrifugation and filtered through a
20 0.45micrometre filter, before beings stored frozen. The virus was subsequently propagated in Vero-118 cells.

Antigen detection by indirect IFA

Samples from experimentally infected monkeys was cultured on Vero-118 cells
25 in 24 well plates containing glass slides. These glass slides were washed with PBS and fixed in acetone for 1 minute at room temperature. After washing with PBS the slides were incubated for 30 minutes at 37 °C with SARS-antibody containing serum from SARS patients. After washing off the human serum in PBS, the slides were incubated at 37°C for 30 minutes with FITC labeled anti-human antibodies. After
30 three washes in PBS and one in tap water, the slides were included in a glycerol/PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The slides were analysed using an Axioscop fluorescence microscope (Carl Zeiss B.V., Weesp, the Netherlands).

35 *Detection of antibodies in humans by indirect IFA*

Virus was cultured on Vero-118 cells in 24 well plates containing glass slides. These glass slides were washed with PBS and fixed in acetone for 1 minute at room temperature. After washing with PBS the slides were incubated for 30 minutes at 37 °C with SARS-antibody containing serum from SARS patients. After washing off the human serum in PBS, the slides were incubated at 37°C for 30 minutes with FITC labeled anti-human antibodies. After three washes in PBS and one in tap water, the slides were included in a glycerol/PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The slides were analysed using an Axioscop fluorescence microscope (Carl Zeiss B.V., Weesp, the Netherlands)

Detection of antibodies in humans by ELISA

Patient samples.

4 samples of patients with SARS disease, 8 samples of patients from routine serological virology; samples from an experimentally infected monkey (preserum, 9 and 12 days after infection).

The Conjugate.

Whole virus was used as the conjugate. Tissue culture supernatant from infected Vero cells were pelleted through 20% sucrose onto a 60% sucrose cushion. The virus was then pelleted through 20% sucrose and resuspended in PBS/1% NP40. After dialysis using PBS, the virus was conjugated to horseradish peroxidase by standard techniques was tested in 3 concentrations (diluted in dilution buffer 9000-03, 1:100, 1:400 and 1:1600), both on polyvalent anti-IgM code MCB0201 (cross-reactive with monkey) and monoclonal anti-IgM, code 9000-62 (non-crossreactive with monkey).

Sera were diluted 1:200 in serum diluent (code 9000-03), monkey 775 was diluted 1: 100, 1:200 and 1:400.

Serum incubation one hour at 37°C, conjugate incubation one hour at 37°C, and TMB (ready to use): 30 minutes at room temperature. The reaction was stopped with sulphuric acid (0.5M).

Virus characterisation

For EM analyses, virus was concentrated from infected cell culture supernatants in a micro-centrifuge at 4 °C at 17000 x g, after which the pellet was
5 resuspended in PBS and inspected by negative contrast EM

RNA isolation

RNA was isolated from the supernatant of infected cell cultures or sucrose
10 gradient fractions using a High Pure RNA Isolation kit according to instructions from the manufacturer (Roche Diagnostics, Almere, The Netherlands).

RT-PCR

A one-step RT-PCR was performed in 50 µl reactions containing 50 mM
15 Tris.HCl pH 8.5, 50 mM NaCl, 4 mM MgCl₂, 2 mM dithiothreitol, 200 µM each dNTP, 10 units recombinant RNasin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de IJssel, The Netherlands) and 5 µl RNA. Cycling conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at
20 42 °C and 3 min. at 72 °C repeated 40 times and 10 min. at 72 °C once.

Primers used for diagnostic PCR:

SARS fwd2: ggtggaacatcatccggtgat

SARS rev2: agcctgtgttagattgcgg

These primers amplify a 149bp fragment of the polymerase gene (orf 1ab)

25 RF 999: TTTAAACACTTACGAGAGTTGTG
RF997: GGACACAACCCATGAAATCATCTGG

These primers amplify a region of 728bp in the spike glycoprotein gene (S)

RF998: AGACATATCTAATGTGCCTTCTCTCC RF1002:

AAGCTCGTCACCTAAGTCATAAGAC (from EMC11 sequence)

30 The combination of RF998/RF1002 primers enabled us to sequence the 3' end of EMC7 – RF998 is a specific primer withing EMC7 whereas EMC1002 acted as a random primer.

RT-PCR, gel purification and direct sequencing were performed as described above.

RAP-PCR

- RAP-PCR was performed essentially as described by Welsh & McClelland (Nuc. Acid Res. 18:7213, 1990; Proc. Natl. Acad. Sci. USA 90:10710 1993). The oligonucleotide sequences are described in addenda 2. For the RT reaction, 2 µl RNA was used in a 10 µl reaction containing 10 ng/µl oligonucleotide, 10 mM dithiotreitol, 500 µM each dNTP, 25 mM Tris-HCl pH 8.3, 75 mM KCl and 3 mM MgCl₂. The reaction mixture was incubated for 5 min. at 70 °C and 5 min. at 37 °C, after which 200 units Superscript RT enzyme (Life Technologies) were added. The incubation at 37 °C was continued for 55 min. and the reaction terminated by a 5 min. incubation at 72 °C. The RT mixture was diluted to give a 50 µl PCR reaction containing 8 ng/µl oligonucleotide, 300 µM each dNTP, 15 mM Tris-HCl pH 8.3, 65 mM KCl, 3.0 mM MgCl₂ and 5 units Taq DNA polymerase (PE Biosystems). Cycling conditions were 5 min. at 94 °C, 5 min. at 40 °C and 1 min. at 72 °C once, followed by 1 min. at 94 °C, 2 min. at 56 °C and 1 min. at 72 °C repeated 40 times and 5 min. at 72 °C once. After RAP-PCR, 15 µl the RT-PCR products were run side by side on a 3% NuSieve agarose gel (FMC BioProducts, Heerhugowaard, The Netherlands). Differentially displayed fragments were purified from the gel with Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands) according to instructions from the manufacturer.

Sequence analysis

- RAP-PCR products cloned in vector pCR2.1 (Invitrogen) were sequenced with M13-specific oligonucleotides. DNA fragments obtained by RT-PCR were purified from agarose gels using Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands), and sequenced directly with the same oligonucleotides used for PCR. Sequence analyses were performed using a Dyanamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). All techniques were performed according to the instructions of the manufacturer.

RT-PCR for diagnosing SARS virus.

For the amplification of the SARS virus' genetic material, we used primers:

SARS fwd2: ggtggaacatcatccggtgat

SARS rev2: agcctgtgtttagattgcgg

These primers amplify a 149bp fragment of the polymerase gene (orf 1ab)

RF 999: TTAAACACTTACGAGAGTTGTG

5 RF997: GGACACAACCCATGAAATCATCTGG

These primers amplify a region of 728bp in the spike glycoprotein gene (S)

These primers amplify a 149bp fragment of the polymerase gene (orf 1ab)

RT-PCR, gel purification and direct sequencing were performed as described above.

10

Phylogenetic analyses

For all phylogenetic trees, DNA sequences were aligned using the ClustalW software package and maximum likelihood trees were generated using the DNA-ML software package of the Phylip 3.5 program using 100 bootstraps and 3 jumbles¹⁸. Previously published sequences for TGEV, PEDV, 229E, AIBV, BoCo and MHV that were used for the generation of phylogenetic trees are available from Genbank

15

Example 2: Methods to identify SARS virus

20 *Specimen collection*

In order to find virus isolates nasopharyngeal aspirates, throat and nasal swabs, broncho alveolar lavages, serum and plasma samples, and stools preferably from mammals such as humans, carnivores (dogs, cats, mustellids, seals etc.), horses, ruminants (cattle, sheep, goats etc.), pigs, rabbits, birds (poultry, ostriches, etc) should be examined. From birds cloaca swabs and droppings can be examined as well. Sera should be collected for immunological assays, such as ELISA, molecular-based assays, such as RT-PCR and virus neutralisation assays.

25

Collected virus specimens were diluted with 5 ml Dulbecco MEM medium (BioWhittaker, Walkersville, MD) and thoroughly mixed on a vortex mixer for one minute. The suspension was thus centrifuged for ten minutes at 840 x g. The sediment was spread on a multispot slide (Nutacon, Leimuider, The Netherlands) for immunofluorescence techniques, and the supernatant was used for virus isolation.

30

Virus isolation

For virus isolation Vero-118 cells or tMK cells (RIVM, Bilthoven, The Netherlands) were cultured in 24 well plates containing glass slides (Costar, Cambridge, UK), with the medium described below supplemented with 10% fetal bovine serum (BioWhittaker, Vervier, Belgium). Before inoculation the plates were washed with PBS and supplied with Eagle's MEM with Hanks' salt (ICN, Costa mesa, CA) supplemented with 0.52/liter gram NaHCO₃, 0.025 M Hepes (Biowhittaker), 2 mM L-glutamine (Biowhittaker), 200 units/liter penicilline, 200 µg/liter streptomycine (Biowhittaker), 1gram/liter lactalbumine (Sigma-Aldrich, Zwijndrecht, The Netherlands), 2.0 gram/liter D-glucose (Merck, Amsterdam, The Netherlands), 10 gram/liter peptone (Oxoid, Haarlem, The Netherlands) and 0.02% trypsin (Life Technologies, Bethesda, MD). The plates were inoculated with supernatant of the patient samples, 0,2 ml per well in triplicate, followed by centrifuging at 840x g for one hour. After inoculation the plates were incubated at 37 °C for a maximum of 1-3 days and cultures were checked daily for CPE. Extensive CPE was generally observed within 24hours. and included detachment of cells from the monolayer..

Virus culture of SARS

Sub-confluent monolayers of tMK cells or Vero clone 118 cells in media as described above were inoculated with supernatants of samples that displayed CPE or with samples taken from patient or artificially infected monkeys..

Virus characterisation

For EM analyses, virus was concentrated from infected cell culture supernatants in a micro-centrifuge at 4 °C at 17000 x g, after which the pellet was resuspended in PBS and inspected by negative contrast EM.

Antigen detection by indirect IFA

Virus was cultured on Vero-118 cells in 24 well slides containing glass slides. These glass slides were washed with PBS and fixed in acetone for 1 minute at room temperature. After washing with PBS the slides were incubated for 30 minutes at 37 °C with SARS patient serum. We used patient serum, but antibodies can be raised in various

animals, such as ferrets, goats and rabbits (for polyclonal antibodies) and mice and hamsters (for monoclonal antibodies), and the working dilution of the antibody can vary for each immunisation. After three washes with PBS and one wash with tap water, the slides were incubated at 37°C for 30 minutes with FITC labeled goat-anti-human antibodies. After three washes in PBS and one in tap water, the slides were included in a glycerol/PBS solution (Citifluor, UKC, Canterbury, UK) and covered. The slides were analysed using an Axiocrop fluorescence microscope (Carl Zeiss B.V., Weesp, the Netherlands).

10 *Detection of antibodies in humans by indirect IFA*

For the detection of virus specific antibodies, SARS virus-infected Vero cells were fixed with acetone on coverslips (as described above), washed with PBS and incubated 30 minutes at 37°C with serum samples at a 1 to 16 dilution. After two washes with PBS and one with tap water, the slides were incubated 30 minutes at 15 37°C with FITC-labelled secondary antibodies to human antibodies (Dako). Slides were processed as described above.

Antibodies can be labelled directly with a fluorescent dye, which will result in a direct immuno fluorescence assay. FITC can be replaced with any fluorescent dye. This technique can be applied to antibodies in other animals such as mammals, 20 ruminants, birds or other species, assuming the secondary antibody to the appropriate species is used.

Detection of antibodies in humans by ELISA

Patient samples.

25 4 samples of patients with SARS; 8 samples of patients from routine serological virology; samples from an experimentally infected monkey (pre-serum and 9 days after infection).

The Conjugate.

30 The conjugate was tested at a number of concentrations, both on polyvalent anti-IgM (cross-reactive with monkey) and monoclonal anti-IgM, (non-crossreactive with monkey).

Sera were diluted 1:200 in serum diluent and the monkey serum was diluted 1: 100, 1:200 and 1:400.

Serum incubation one hour at 37°C, conjugate incubation one hour at 37°C, and TMB (ready to use): 30 minutes at room temperature. The reaction was stopped with
5 sulphuric acid (0.5M).

Results were interpreted by eye. Three of the four SARS-IgM positive sera (as detected by IF on infected cells) had a higher score than negative control sera. One serum had a score which was also reached by some of the negative controls. The 9 day
10 old monkey sera did not react, but the 12 day old did. Thus, this study shows that with direct conjugation of nucleocapsids the development of an IgM capture method is feasible.

Furthermore, this type of assay can be performed in a number of formats by those trained in the art. The assay can be extended to the detection of IgA and IgG
15 antibodies from humans and animals and can make use of different capture antigens, such as, but not limited to, purified recombinant N protein.

Animal immunisation

Cynomolgous macaque specific antisera for the newly discovered virus were
20 generated by experimental intratracheal installation of cultured virus of Cynomolgous macaques. One to two weeks later the animals were bled. The sera were tested for reactivity to SARS virus by indirect IFA as described above; uninfected control cells were used to ensure the specificity of the serum. Other animal species are also suitable for the generation of specific antibody preparations
25 and other antigen preparations may be used.

RNA isolation

RNA was isolated from the supernatant of infected cell cultures or sucrose
30 gradient fractions using a High Pure RNA Isolation kit according to instructions from the manufacturer (Roche Diagnostics, Almere, The Netherlands). RNA can also be isolated following other procedures known in the field (*Current Protocols in Molecular Biology*).

RT-PCR

A one-step RT-PCR was performed in 50 µl reactions containing 50 mM Tris.HCl pH 8.5, 50 mM NaCl, 4 mM MgCl₂, 2 mM dithiothreitol, 200 µM each dNTP, 10 units recombinant RNasin (Promega, Leiden, the Netherlands), 10 units AMV RT (Promega, Leiden, The Netherlands), 5 units Amplitaq Gold DNA polymerase (PE Biosystems, Nieuwerkerk aan de IJssel, The Netherlands) and 5 µl RNA. Cycling conditions were 45 min. at 42 °C and 7 min. at 95 °C once, 1 min at 95 °C, 2 min. at 42 °C and 3 min. at 72 °C repeated 40 times and 10 min. at 72 °C once.

Primers used for diagnostic PCR:

For the amplification of the SARS virus' genetic material, we used primers:

SARS fwd2: ggtggaacatcatccggtgat

SARS rev2: agcctgtgtgttagatgacgg

These primers amplify a 149bp fragment of the polymerase gene (orf 1ab)

RT-PCR, gel purification and direct sequencing were performed as described above.

Sequence analysis

Sequence analyses were performed using a Dyenamic ET terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystem). All techniques were performed according to the instructions of the manufacturer. PCR fragments were sequenced directly with the same oligonucleotides used for PCR, or the fragments were purified from the gel with Qiaquick Gel Extraction kit (Qiagen, Leusden, The Netherlands) and cloned in pCR2.1 vector (Invitrogen, Groningen, The Netherlands) according to instructions from the manufacturer and subsequently sequenced with M13-specific oligonucleotides.

Detection of antibodies in humans, mammals, ruminants or other animals by ELISA

A recombinant protein derived from the SARS virus is preferred as the antigen. However, purified nucleocapsids may also be used. Antigens suitable for antibody detection include any SARS protein that combines with any SARS-specific antibody of a patient exposed to or infected with SARS virus. Preferred antigens of the invention include those that predominantly engender the immune response in

patients exposed to SARS, which therefore, typically are recognised most readily by antibodies of a patient. Particularly preferred antigens include the N, and S proteins of SARS.

Antigens used for immunological techniques can be native antigens or can be modified versions thereof. Well known techniques of molecular biology can be used to alter the amino acid sequence of a SARS antigen to produce modified versions of the antigen that may be used in immunologic techniques.

Methods for cloning genes, for manipulating the genes to and from expression vectors, and for expressing the protein encoded by the gene in a heterologous host are well-known, and these techniques can be used to provide the expression vectors, host cells, and the for expressing cloned genes encoding antigens in a host to produce recombinant antigens for use in diagnostic assays. See for instance: *Molecular cloning, A laboratory manual* and *Current Protocols in Molecular Biology*.

A variety of expression systems may be used to produce SARS antigens. For instance, a variety of expression vectors suitable to produce proteins in *E.Coli*, *B.subtilis*, yeast, insect cells and mammalian cells have been described, any of which might be used to produce a SARS antigen suitable to detect anti- SARS antibodies in exposed patients.

The baculovirus expression system has the advantage of providing necessary processing of proteins, and is therefor preferred. The system utilizes the polyhedrin promoter to direct expression of SARS antigens. (Matsuura et al. 1987, J.Gen.Virol. 68: 1233-1250).

Antigens produced by recombinant baculo-viruses can be used in a variety of immunological assays to detect anti- SARS antibodies in a patient. It is well established, that recombinant antigens can be used in place of natural virus in practically any immunological assay for detection of virus specific antibodies. The assays include direct and indirect assays, sandwich assays, solid phase assays such as those using plates or beads among others, and liquid phase assays. Assays suitable include those that use primary and secondary antibodies, and those that use antibody binding reagents such as protein A. Moreover, a variety of detection methods can be used in the invention, including colorimetric, fluorescent, phosphorescent, chemiluminescent, luminescent and radioactive methods.

Example 3: Animal models

Macaques

Four Cynomologous Macaques were infected with SARS virus by intratracheal installation using Vero-118 cell derived virus.

The monkeys had the following clinical symptoms

- Lethargy
- One of four monkeys had severe pneumonia
- Mild to severe rash in the inguinal region and the axilar region
- Watery stools

After 10-16 days the monkeys were euthanized. Tissues were examined and the following was found

- Alveolae were filled with serum and their architecture were disrupted, consistent with bronchointestinal pneumonia (see fig 5 and b)
- Multi-cell syncytia in lungs (fig 5c)
- Multi-cell syncytia in kidneys (fig 5d)
- Widening of the small intestine

Virus was detected using RT-PCR on tissue samples and by culturing samples followed by electron microscopy from

- Lungs
- Nasal swabs
- Throat swabs
- Faeces
- Kidneys

The EM results demonstrate that the virus that was recovered from the Cynomologous Macaques had the identical morphology to the virus which was used to infect them.

This demonstrates that Cynomologous Macaques may be used as animal models to tests the efficacy of pharmaceutical preparations for therapeutic or prophylactic purposes

Cats and ferrets

Domestic cats (n = 6) and ferrets (n = 6) were inoculated intratracheally with 106 median tissue culture infectious dose (TCID₅₀) SCV, obtained from patient 5688 who died from SARS and passaged four times on Vero 118 cells in vitro. Nasal, pharyngeal and rectal swabs were taken on different days post infection (d.p.i.). Four animals of each group were euthanised at 4 d.p.i. and necropsy was performed according to a standard protocol. No clinical signs were observed in SCV-inoculated cats, while three out of six ferrets became lethargic from 2 to 4 d.p.i. and one of these ferrets died at 4 d.p.i. All cats and ferrets (Fig. 7) shed SCV from the pharynx starting at 2 d.p.i. until day 10 and 14, respectively, as determined by RT-PCR. Virus was isolated from all pharyngeal swabs taken on 2-8 d.p.i. and nasal swabs of two cats on 4 and 6 d.p.i.. SCV was detected neither in nasal swabs from ferrets nor in rectal swabs of cats or ferrets. Infection of the respiratory tract was evident in all animals tested; SCV could be isolated from their tracheas and lungs (Fig 8). Quantification of the mean geometric viral titres per ml lung homogenate revealed relatively low SCV titers in the lungs of SCV-inoculated cats ($1 \times 10^3 \pm 0.51$ TCID₅₀) compared to ferrets ($1 \times 10^6 \pm 0.70$ TCID₅₀). Histologically, SCV infection was associated with pulmonary lesions similar to those in SCV-infected macaques, except that they were milder, especially in SCV infected cats and syncytia were not found. In the gastro-intestinal and urinary tracts SCV was detected by RT-PCR (Fig 8). Follow up of the remaining SCV-inoculated animals (n = 2 per group) revealed that they all had seroconverted by 28 d.p.i. (neutralising antibody titers 40-320). Two attempts to infect suckling mice through intracerebral inoculation failed.

Non-inoculated cats (Fig 7c, n = 2) and ferrets (Fig 7d, n = 2) housed together with the inoculated cats and ferrets, respectively, became infected with SCV; viral titers gradually increased from day 2 onwards and peaked at 6 to 8 d.p.i. Neither of the cats showed clinical signs but had seroconverted by day 28 (virus neutralising antibody titres of 40 and 160). Both ferrets showed lethargy and conjunctivitis and died on 16 and 21 d.p.i. Based on pathologic examination, the main lesions in these two animals were marked hepatic lipidosis and emaciation. There was no evidence that either of these animals died of SCV-associated pneumonia, although SCV was isolated from postmortem lung specimens of one animal.

In conclusion, domestic cats and ferrets are susceptible to experimental SCV infection and transmission of SCV to non-inoculated animals occurs efficiently. Both

species potentially could be used as animal models to test antiviral drugs or vaccine candidates against SARS.

5 Example 4: SARS- interferon experiments

In a first experiment four groups of two monkeys were injected.

1. PEG-INTERFERON treatment

- 10 Dose: 3 µg/kg or PBS injected intramuscularly according the following scheme:

Monkey:

- | | | | |
|----|------|-----|---|
| | M001 | PBS | at days -3, -1, +1 and +3 |
| 15 | M002 | PBS | at days -3, -1, +1 and +3 |
| | M003 | IFN | at days -3, -1, +1 and +3 |
| | M004 | IFN | at days -3, -1, +1 and +3 |
| 20 | M005 | PBS | at d. -3 and -1 and IFN at d. +1 and +3 |
| | M006 | PBS | at d. -3 and -1 and IFN at d. +1 and +3 |
| | M007 | IFN | at days -3, -1, +1 and +3 |
| | M008 | IFN | at days -3, -1, +1 and +3 |
| 25 | | | |

2. Infection

SARS coronavirus infection of all monkeys on day 0

30

Dose: 10⁶ TCID 50 in 5 ml PBS

- 4 ml intra-tracheal
- 1 ml intranasal
- 0.5 ml on each of the eyes

35

3. Sampling

a. Nose throat and rectum swabs taken on days 0, 2 and 4 and were put in 1 ml transport medium.

b. Monkeys were euthanised on day 4 and samples of lung, tracheal
bronchial lymph node and trachea were harvested

Virus was cultured and titrated on Vero-118 cells, and these were scored for cytopathic effects

Virus titration using the three different swabs taken on days 0, 2 and 4 after infection (nose, throat and rectum) and isolation of virus from the lungs, tracheal
bronchial lymph node and trachea at day 4 after infection demonstrated that the two control monkeys (M001 and M002) were successfully infected (table 1).

Table 1 SARS-associated coronavirus excretion by cynomolgus macaques treated with pegylated interferon.

Animal no.	specimen*					
	Pharyngeal swab			Tr. Br lymph node	Trachea	Lung
	0	2	4	4	4	4
M001	-	+	+	+	+	+
M002	-	+	+	+	+	++
M003	-	-	-	-	-	+
M004	-	-	-	+	-	+
M005	-	+	-	-	+	++
M006	-	+	-	+	+	++
M007	-	-	-	n.a.	n.a.	n.a.
M008	-	-	-	n.a.	n.a.	n.a.

* day post infection

1. Control animals (M001, 002)

- Pharyngeal swabs on days 2 and 4 were all positive
- Animal M001 also was found positive with respect to isolation of SARS coronavirus from the nasal swab (day 2 and 4).
- No rectal swabs were positive

- Tissue specimen from the lungs, trachea and trachea bronchial lymph node from both control animals (M001 and M002) were positive at day 4 when the animals were sacrificed. The lung tissue homogenate contained virus at a high titer because the Vero cultures were found positive rapidly after inoculation.

5

2. Prophylactically treated animals (M003, 004, 007 & 008)

- negative with respect to the virus isolation test on pharyngeal swabs taken at day 0, 2 and 4 after infection (table 1).
- No nasal swab was found positive in these animals.
- Only one rectal swab of animal M004 at day 4 was scored positive (which has to be confirmed in the PCR assay because these cultures showed much bacterial contamination (cultures of rectal swabs))
- No virus isolated from trachea of M003 and 004.
- Virus isolated from tracheal bronchial lymph node of M004 but not M003
- Virus isolated from lungs of M003 and 004, but are at lower titre than controls as it took longer for CPE to be observed in Vero-118 cells inoculated with samples from the lungs (confirmed by PCR – figure A below)

20 3. Therapeutically treated animals (M005 and 006)

SARS coronavirus

- isolated from pharyngeal swabs taken at day 2 after infection
- not isolated from the pharyngeal swabs taken at day 4 after infection.
- isolated from more tissue samples and at higher titers from animal M005 and M006, than from animal M003 and M004 (quantitation confirmed by PCR)

Pathological examination of lung section stained by HE confirmed the low level infection of the lungs of animal M003.

30

In a second experiment treatment of Cynomolgus macaques was preceded by an *in vitro* dose-finding experiment on Vero cells.

In vitro study

Wells containing Vero cells were treated in triplicate with pegylated recombinant IFN- α (PEG-Intron, Shering Corp) for 16 h and infected with 100 TCID₅₀ per well of SCV, obtained from patient 5688, who died of SARS. After 16 h the supernatant was removed and cells were fixed by 10% neutral-buffered formalin and 70% ethanol (10 min ET). SCV antigen positive cells were visualised by immunohistochemistry, as described under histology. The number of SCV-infected cells per well was summarized as mean \pm s.d..

10 *Macaque studies.*

Three groups of cynomolgus macaques were infected intratracheally with 1×10^6 TCID₅₀ SCV suspended in 5 ml of phosphate buffered saline (PBS). One (the control group, $n = 4$) was injected intramuscularly with PBS and two (the prophylactic group, $n = 6$; the post-exposure group, $n = 4$) with pegylated IFN- α at a dose of 3 μ g/kg. The prophylactic group was injected with pegylated IFN- α at days -3, -1, 1 and 3 after SCV infection and the post-exposure group at days 1 and 3 after SCV infection. Four macaques from each group were euthanised at day 4 after infection. Approval for the animal experiments had been obtained from the Institutional Animal Welfare Committee. At days -3, -2, -1, 0, +2 and +4, we anaesthetised the macaques with ketamine and collected 10 ml blood from inguinal veins and took pharyngeal swabs, which were placed in 1 ml transport medium (Fouchier, R.A. *et al.*, J. Clin. Microbiol. 38, 4096-5001). Pharyngeal swabs were frozen at -70 °C until RT-PCR analysis. Pegylated IFN- α levels were determined using an ELISA (Bender MedSystems Diagnostics) using PEG-Intron as a standard and neopterin levels were determined as described by van Gool *et al.* (Psychiatry Res. 119, 125-132, 2003). Necropsies were done according to a standard protocol; one lung of each monkey was inflated with 10% neutral-buffered formalin by intrabronchial intubation and suspended in 10% neutral-buffered formalin overnight. Samples were collected in a standard manner (one from the cranial part of the lung, one from the medial and two from the caudal part), embedded in paraffin, cut at 5 μ m and used for immunohistochemistry (see below) or stained with haematoxylin and eosin (HE). For semiquantitative assessment of SCV-infection-associated inflammation in the lung, each HE-stained section was examined for inflammatory foci by light microscopy using a 10 \times objective. Each focus was scored for size (1: smaller than or equal to area of 10 \times objective, 2: larger than area of 10 \times objective and smaller than or equal to area

of 2.5× objective, 3: larger than area of 2.5× objective) and severity of inflammation (1: mild, 2: moderate, 3: marked). The cumulative scores for the inflammatory foci provided the total score per animal. Sections were examined without knowledge of the identity of the macaques. The lung sections of one monkey in the post exposure group were not assessed because of the presence of inflammation from pre-mortem aspiration of food remains. Lung samples from a control group macaque were used for transmission electron microscopy as described by Kuiken, T. *et al.* (Lancet 362, 263-270, 2003).

Three lung tissue samples taken from the other lung (one from the cranial part of the lung, one from the medial part, and one from caudal part) were homogenised in 2 ml transport medium using Polytron PT2100 tissue grinders (Kinematica). After low speed centrifugation, the homogenates were frozen at -70° C until inoculation on Vero 118 cell cultures in 10-fold serial dilutions. The identity of the isolated virus was confirmed as SCV by RT-PCR of supernatant.

Immunohistochemistry

The same formalin-fixed paraffin-embedded lung samples as used for histology – one from the cranial part of the lung, one from the medial part, and two from caudal part – were cut at 5 µm, and stained for SCV antigen using a biotinylated purified human IgG from a convalescent SARS patient, negative control biotinylated purified human IgG, or the dilution buffer, as described by Kuiken *et al.* (*supra*). Twenty-five arbitrarily chosen 20× objective fields of lung parenchyma in each lung section were examined by light microscopy for the presence of SCV antigen expression, without knowledge of the identity of the macaques. The cumulative scores for each animal were expressed as number of positive fields per 100 fields (%). Selected lung sections from macaques in the control group were stained with anti-cytokeratin monoclonal antibody AE1/AE3 (Neomarkers) for identification of epithelial cells, according to standard immunohistochemical procedures.

SCV RT-PCR

An RT-PCR with primers and probe specific for the nucleoprotein (NP) gene of SCV was used to quantificate SCV in swabs as described by Kuiken *et al.* (*supra*). Serial dilutions of the SCV stock were used as a standard and the results were expressed as SCV eq/ml swab medium.

Results

The dose finding study (3 separate experiments) on Vero cells showed a dose-dependent effect on the numbers of SCV infected cells per well. A significant effect was already observed at a dose of 1 ng/ml drug, while a dramatic reduction in the number of infected cells was observed at doses higher than 1 ng/ml (fig. 11a).

The control macaques showed multifocal acute DAD (diffuse alveolar damage), characterized by flooding of alveoli with protein-rich oedema fluid mixed with neutrophils and rare syncytia, extensive loss of alveolar and bronchiolar epithelium and occasional type 2 pneumocyte hyperplasia. As indicated by immunohistochemistry, there was extensive SCV antigen expression of squamous cells lining the alveolar walls. They were indicated as type 1 pneumocytes by their location, morphology, and expression of keratin in serial sections. By transmission electron microscopy, coronavirus-like particles measuring about 70 nm in diameter with typical internal nucleocapsid-like structure were found in alveolar cells. These cells were identified as type 1 pneumocytes because they lined the alveolar lumen, were closely apposed to the basement membrane, were squamous, contained abundant pinocytotic vesicles, and – in contrast to type 2 pneumocytes – had neither lamellar bodies nor microvilli. As found previously in experimentally infected macaques at 6 d.p.i., less extensive SCV antigen expression also was detected in hyperplastic type 2 pneumocytes within inflammatory foci. The combination of these histopathologic and immunohistochemical findings show that type 1 pneumocytes are the main target of SCV in early infection, and are associated with DAD.

High plasma levels of pegylated IFN- α after intramuscular injection into a group of six macaques (prophylactic group) were attained 1 day after injection (Fig. 11b), similar to peak levels found in patients after subcutaneous injection with 3 μ g/kg pegylated IFN- α (Bukowski, R.M. *et al.*, Cancer 95, 389-396, 2002). Because IFN- α is known to activate macrophages (van Gool *et al.*, *supra*), plasma levels of neopterin following pegylated IFN- α treatment were measured as a measure of

macrophage activation. Neopterin levels were increased in all animals (Fig. 11c), confirming the biological availability of pegylated IFN- α in the treated macaques.

To evaluate the prophylactic use of pegylated IFN- α , we experimentally infected the macaques in the prophylactic group with SCV at 3 days after the start of pegylated IFN- α treatment, and compared virological and pathological parameters with a control group of four macaques treated with PBS instead. We limited our investigation to the pharyngeal swabs and the lung because an earlier study did not provide evidence of extensive viral replication in other organs (Kuiper *et al.*, *supra*). We found that all parameters were significantly reduced in the prophylactic group compared to the control group. By virology, virus excretion from the pharynx was abrogated (Fig. 12), and the virus titre in the lungs at 4 d.p.i. was significantly reduced (Fig. 13a). By immunohistochemistry, the expression of SCV in type 1 pneumocytes was 90% reduced (Fig. 13b). By pathology, the extent and severity of DAD was 80% reduced (Fig. 13c). These data demonstrate that prophylactic use of pegylated IFN- α substantially, although not completely, protects type 1 pneumocytes of experimentally infected macaques from SCV infection, with abrogation of virus excretion and reduced severity of pulmonary lesions.

To test the efficacy of pegylated IFN- α as an antiviral agent post-exposure, we injected pegylated IFN- α intramuscularly into a post-exposure group of four macaques 1 and 3 days after experimental SCV infection, and evaluated them in the same way as the prophylactic group. Excretion of SCV from the pharynx was found only on 2 d.p.i. at a significantly reduced level compared to the control group (Fig. 12). Moreover, the virus titre in the lungs at 4 d.p.i. was significantly decreased, whereas the remaining parameters were less reduced (Fig. 13a-c). These results show that use of pegylated IFN- α one day post-exposure protects type 1 pneumocytes of experimentally infected macaques from SCV infection but is less effective than prophylactic use.

In this study, we have shown that type 1 pneumocytes are the main target cell for SCV infection of cynomolgus macaques early in the disease, and that pegylated IFN- α protects type 1 pneumocytes from SCV infection. The first point—type 1 pneumocytes as the primary target cell—is evident from the extensive presence of SCV in type 1 pneumocytes at 4 d.p.i.). The temporal sequence of lung lesions that emerges when the pathological studies in humans and macaques are viewed together is: viral infection and subsequent loss of type 1 pneumocytes; acute DAD,

characterized by flooding of alveolar lumina with highly proteinaceous oedema fluid; chronic DAD, characterized by type 2 pneumocyte hyperplasia; and, in severe cases, extensive pulmonary fibrosis. This sequence of events corresponds to the stereotypic alveolar reaction to acute lung injury from a variety of causes (Ware, L.B. and Matthay, M.A., *N. Eng. J. Med.* 342, 1334-1349, 2000).

The second point—that pegylated IFN- α protects type 1 pneumocytes from SCV infection—is based on the beneficial effect of pegylated IFN- α therapy initiated 3 days before SCV inoculation of macaques. In these macaques, SCV infection of type 1 pneumocytes and severity of lung lesions were significantly reduced (Fig. 13), and viral excretion was abrogated (Fig. 12). Pegylated IFN- α treatment thus has an important effect on the outcome of SARS. Therefore, reduction of the viral load by pegylated IFN- α therapy at an early stage of SCV infection helps to prevent serious or fatal outcome of SARS associated with pulmonary fibrosis. In addition to potential disease mitigation, reduced viral excretion through pegylated IFN- α therapy also has an epidemiological effect by reducing the spread of SCV in the human population. Whether the mechanism of pegylated IFN- α protection is by direct antiviral activity or immunostimulatory effects remains to be determined.

The time interval during which effective post-exposure treatment with pegylated IFN- α can be initiated may be longer in humans than in the experimentally infected macaques. This is because the peak of SCV infection in the lungs is at about 16 d.p.i. in humans—based on an average incubation period of 6 days (Booth, C.M. *et al*, *JAMA* 289, 2801-2809, 2003) and a peak in viral excretion at 10 days after onset of symptoms (peiris, J.S.M. *et al*, *Lancet* 361, 1767-1772, 2003)—compared to 2 d.p.i. in these macaques (Fig. 12).

In conclusion, these studies show that type 1 pneumocytes are the main target cell for SCV infection of macaques early in the disease, and that pegylated IFN- α , a commercially available antiviral drug, protects these cells from SCV infection. Prophylactic or early post-exposure treatment with pegylated IFN- α will help to reduce the impact of SCV infection on healthcare workers and others possibly exposed to SCV and to limit the spread of the virus in the human population.

Claims

1. An isolated essentially mammalian positive-sense single stranded RNA virus (SARS) comprising one or more of the sequences of figure 2.
- 5 2. An isolated positive-sense single stranded RNA virus (SARS) belonging to the Coronaviruses and identifiable as phylogenetically corresponding thereto by determining a nucleic acid sequence of said virus and testing it in phylogenetic tree analyses wherein maximum likelihood trees are generated using 100 bootstraps and
10 3 jumbles and finding it to be more closely phylogenetically corresponding to a virus isolate having the sequences as depicted in figure 2 than it is corresponding to a virus isolate of BoCo (bovine coronavirus), MHV (murine hepatitis virus), AIBV (avian infectious bronchitis virus), PEDV (porcine epidemic diarrhea virus), TGEV (transmissible gastroenteritis virus) or 229E (human coronavirus 229E)..
- 15 3. A virus according to claim 1 or 2 wherein said nucleic acid sequence comprises an open reading frame (ORF) encoding a viral protein of said virus.
4. A virus according to claim 3 wherein said open reading frame is selected from
20 the group of ORFs encoding the viral replicase, nuclear capsid protein and the spike protein.
5. A virus according to claim 1-4 isolatable from a human with atypical pneumonia.
- 25 6. An isolated or recombinant nucleic acid or SARS virus-specific functional fragment thereof obtainable from a virus according to anyone of claims 1 to 5.
7. A vector comprising a nucleic acid according to claim 6.
- 30 8. A host cell comprising a nucleic acid according to claim 6 or a vector according to claim 7.

9. An isolated or recombinant proteinaceous molecule or SARS virus-specific functional fragment thereof encoded by a nucleic acid according to claim 6.
10. An antigen comprising a proteinaceous molecule or SARS virus-specific functional fragment thereof according to claim 9.
11. An antibody specifically directed against an antigen according to claim 10.
12. A method for identifying a viral isolate as a SARS virus comprising reacting said viral isolate or a component thereof with an antibody according to claim 11.
13. A method for identifying a viral isolate as a SARS virus comprising reacting said viral isolate or a component thereof with a nucleic acid according to claim 6.
14. A method for virologically diagnosing a SARS infection of a mammal comprising determining in a sample of said mammal the presence of a viral isolate or component thereof by reacting said sample with a nucleic acid according to claim 6 or an antibody according to claim 11.
15. A method for serologically diagnosing a SARS infection of a mammal comprising determining in a sample of said mammal the presence of an antibody specifically directed against a SARS virus or component thereof by reacting said sample with a proteinaceous molecule or fragment thereof according to claim 9 or an antigen according to claim 10.
16. A diagnostic kit for diagnosing a SARS infection comprising a virus according to anyone of claims 1 to 5, a nucleic acid according to claim 6, a proteinaceous molecule or fragment thereof according to claim 9, an antigen according to claim 10 and/or an antibody according to claim 11.
17. Use of a virus according to any one claims 1 to 5, a nucleic acid according to claim 6, a vector according to claim 7, a host cell according to claim 8, a proteinaceous molecule or fragment thereof according to claim 9, an antigen according to claim 10,

or an antibody according to claim 11 for the production of a pharmaceutical composition.

18. Use according to claim 17 for the production of a pharmaceutical composition
5 for the treatment or prevention of a SARS virus infection.

19. Use according to claim 17 or 18 for the production of a pharmaceutical composition for the treatment or prevention of atypical pneumonia.

10 20. A pharmaceutical composition comprising a virus according to any one of claims 1 to 5, a nucleic acid according to claim 6, a vector according to claim 7, a host cell according to claim 8, a proteinaceous molecule or fragment thereof according to claim 9, an antigen according to claim 10, or an antibody according to claim 11.

15 21. A method for the treatment or prevention of a SARS virus infection comprising providing an individual with a pharmaceutical composition according to claim 20.

22. A method for the treatment or prevention of atypical pneumonia comprising providing an individual with a pharmaceutical composition according to claim 20.
20

23. A viral replicase encoded by an RNA sequence comprising the sequences EMC-1, EMC-2, EMC-3, EMC-4, EMC-5, EMC-6, EMC-7, EMC-13 and/or EMC-14, or homologues thereof as depicted in figure 2.

25 24. A viral spike protein comprising the amino acid depicted as translation 2 with sequence EMC-7 and translation 1 of RDG 1 as depicted in figure 2, or a homologue thereof.

25 25. A viral nuclear capsid protein encoded by an RNA sequence comprising the
30 sequence EMC-8 as depicted in figure 2 or a homologue thereof.

26. A viral protein encoded by an RNA sequence comprising the sequence EMC-9, EMC-11 and/or EMC-12 as depicted in figure 2.

27. A nucleic acid sequence which comprises one or more of the sequences EMC-1 to EMC-13 as depicted in figure 13 or a nucleic acid sequence which can hybridise with any of these sequences under stringent conditions.
- 5 28. Use of interferon for the preparation of a medicament for the treatment or prevention of a coronavirus associated disease.
29. Use according to claim 28 wherein said interferon is interferon
10 alpha.
30. Use according to claim 29, wherein said interferon is interferon-
alpha 2a.
31. Use according to claim 29, wherein said interferon is interferon-
15 alpha 2b.
32. Use according to any of claims 28-31, wherein said interferon is pegylated.
33. Use according to any of claims 28-32, wherein said coronavirus associated
20 disease is a disease of animals, preferably vertebrates, more preferably birds or mammals, especially humans, ape or rodent.
34. Use according to claim 33, wherein said disease is a respiratory disease and/or
gastroenteritis.
- 25 35. Use according to claim 33 or claim 34, wherein said animal is human.
36. Use according to any of claims 28-35 wherein said coronavirus associated
disease is a disease caused by HCoV-NL, the feline infectious peritonitis virus (FIPV)
30 or hemagglutinating encephalomyelitis virus (HEV) of swine or avian infectious
bronchitis virus (IBV) or mouse hepatitis virus (MHV).
37. Use according to any of claims 28-35 wherein said coronavirus associated
disease is a disease caused by a SARS coronavirus (SARS-CoV).

38. Use according to claim 37, wherein said SARS virus is a positive-sense single stranded RNA virus (SARS coronavirus) comprising one or more of the sequences of figure 2.

39. Use according to claim 28, wherein said SARS virus is a positive-sense single stranded RNA virus (SARS coronavirus) corresponding to GenBank accession no. AY274119 or AY278741 or AY338175 or AY338174 or AY322199 or AY 322198 or AY322197 or AH013000 or AY322208 or AY322207 or AY 322206 or AY322205 or AH012999.

40. A method for the treatment or prevention of a coronavirus associated disease in an animal, preferably a vertebrate, more preferably a bird or mammal, especially human, ape or rodent, infected with a coronavirus, said method comprising administering interferon, to said animal, preferably a vertebrate, more preferably a bird or mammal, especially human, ape or rodent, along with a pharmaceutically acceptable carrier.

41. A method according to any of claims 40 wherein said interferon is administered together with a vaccine, antibody and/or antiviral agent.

42. A method according to claim 41, wherein said vaccine, antibody and/or antiviral agent is selected from the group consisting of whole inactivated virus vaccines, attenuated vaccines, sub-unit vaccines, recombinant vaccines, antibody for passive immunization, nucleoside analogs such as ribavirin, RNA-dependent RNA polymerase inhibitors, protease inhibitors.

Figure 1.




Figure 2 RNA sequences, implied polypeptides and alignment with one close relative

EMC-1

5 UUGUAAACUGSGUGGUUUUUGUACACACAGACUUCUCAGUGSGUUGUCUAAUUCUUUUGGCGCAUUCUGSUUGAAAAAC
UCAGGCGCUAUUCUUUGAAGGCAUUGAGGCGAUAUCUUNUGSGAGGAGUUGAAUUCUCCAGGAUUCUGUUGGAGAUU
UGUCUCAAUUUCUCAUAUUCAGGUUUUUUGCAUCGCAAGGUGUCAAUACAGUUGUCUUCAGCAUAACACUACAG
GAUUGUUGUAAAUGGUCUUAUUGUUGUUGUUAACAGGCGCAUUAAGUUGGCAUUGAGUACGAGGACACUACUGCGUC
GCGCAAGUUGGCGAUCAUCACUACUAGGUGUAGGUCUUAUCGCGUCAAAGCAGGAGCAUUAACGCGUAGCGUUAU
10 ACGUGGCGAAGGACAGCUGCAUGCAUCUACUGGCCUUAUAGGCGACAAAAGAAUGUAACUUUCUUA
UGAAGGUGUAUACAGACACACAGCAUGUACUUAACGUCUGAGGAGGUUGUUCUCAAAGAACGGUGUAAU
CUCGAAAGCAUCUGGAGCGCGCCGUUGAAGUCUACAAUAGGAGCUAUUGUUGGCGACUACUG
UCUGUUGAUAUGGCGCUAUGGUCUUAAGAGUAUAGGACAAAGAACAAUUAUCUGCGCAUACUG
UCCUGGUUUUACUGGCGUACAACAUAUGUCUUAUCGCUUAAAAGGGGGUGCAACCAUUAAGGU
15 UUAACCUUUGGAGAAUAUACUGUUUUGGGAAGUUCAGGGUUAACAAGAAUUGUGAGAAUCUUGA
GUGACGCUAGUAAGAACUGGUUGAACAAGGUCUUAUAGGAAUAGGUCGUCUGUACACUGUUGA
AUCGCGUACCGAAGUAUCUAGAGUUGUAGCUGUUGUAGCAGAGGCGUUGUGAAGACUUAU
CAACAGUUUUCUGACU

20 TranslationNucleotides 7 to 870; Frame 1; 288 aa

LVLVLYNRLLSGCLIFWALLVEKLRPIFEWIEAKLSAGVEFLKDAWEILKFLITGVFDIVKQIQVASDNIKDCVCKCFDIVV
NKALEMCIQDQVTAGAKLRSLNLGEVFTAQSGKLYRQCIRGKEQLQLLMLPKAPKEVTFLEBGDSHDTVLTSEEVVLKNGEL
EALETVPVDSFTNGAIVGTGPCVNGLMTLEIKDKBQYCALSPGLLTANNVFRCLKGGAPIKGVTFEGDVTWEVQGYKNVRITF
ELDERDVFNLEKCSVTVESGTEVFACVVAEAVVTKLPVPSD

Alignment

RNA-directed RNA polymerase (orf1a) murine hepatitis virus
Identities = 72/285 (25%), Positives = 118/285 (41%)

30 Query: 49 FWALLVEKLRPIFEWIEAKLSAGVEFLKDAWEILKFLITGVDFIVKGQIQVASDNKDCV 228
F AL V +R I EW + L+ + W + L+ G+F + G I + + + V
Sbjct: 638 FKALGVAVVRKITEWFD--LAVDIAASAGWLCYO-LVNGLFAVANGVITFVQV-VPELV 693

35 Query: 229 KCFIDVVNKALEMCIDQVTIA---GAKLRSLNLGEVFIAQSGLYRQCIRGKEQLQLLMP 399
K F+D ++ ID ++++ G + V +A SK +Y + K +MP
Sbjct: 694 KNEVDKFKAFFKVLIDSMVSILSGLTVVKTASNRVCLAGSK-VY2--VVKLSLAVYMP 750

Query: 400 LKAPKEVTFLEGSDHDTVLTSSEVVLKNGEL--EALETVPVDSFTNGAIVGTPVCVNGML 573
+ E T L G+ V + V + L + P S F I V L
40 Sbjct: 751 VGC-SEATCLVGEIEPAVFEDDVVDVVKAPLTYQGCKPPTSFEKICIVDK-----L 801

Query: 574 LEIKDKEQYCAL-----SPGLLATNNVFRKKGAPIKGVTFGEDT-VVEVQGYKNVRITF 735
K +Q+ + + G+L F G K V F + V ++ + ++ITF
Sbjct: 802 YMAKCGDQFYPVVVDNDTVGLVDQWRFPAG----KKVEFNDKPKVRKIPSTRKIKITF 857

Query: 736 ELDERVDKVLNEKCSVYTVESGTEVTEFACVVAEAVVKTLQPVSD 870
LD D VL++ CS + V+ + E VV +AV TL P +
Sbjct: 858 ALDATFDSVLKACSEFEVDKDVTLDELDDVVLDAVESTLSPCKE 902

50 EMC-14

55 CAUCCAGCUUCUUAAGGCAGCAUAUGAAAAUUUCAAUUCACAGGACAUCUUAUCUGCACAUAUUGUUCAGCA
GGCAUAUUGUGGCUAAACCAUCCUAGCUUUUACAGUUGUGGUGGUGCAGACGGUUCUGACAGCAUUAUAUUG
CAGCAUAUGACAAGCUUCUUUAGGACAGGUUUGUGAUGGAUUAUUCUAGAACCTGGAAGCUCAGAGUGGAAGC
ACCUAAACAGAGGAGGCCACAAACACAGAGAAGUUCUAAAACUAGGAGGAUAUCUUCUGCACAAGGCCUCU
GAGUGGAGGCCAGAAAUUAAGGCCGUGCAUGAUGAGGUAUUCCACAAUCUGGAGGAAGAAUAAGUUAUUCACCA
AUAAGUAUACUCUUGUUUGUGCAUAUAACAGUGGAAGCUUUUCCAGUAUUCUGACAGAUUCUGGAGGUGAAGA
UADUGUUUUUCUGGAGGAGGAUGACCCUUAACUAGUGAGUGAGUGAUAUACCAUAGGUGGUGAUAACCAUUGDU

Fig. 2 Cont.

GUAAUACCCUCCAAAAGGCGUGGACUACUGAGUCUCUACAAGAGCUUUGAAGAAAGUGCCAGUUGAG
AGUUAUAUACACGUAUCCUGGACAGGAGUGUGUGGUUAUACACUAGGAGAGCUAGACUGCUCUUAAGAA
AUGCAAAUCUGCAUUUUUGUACUACCUCAAGAAGACCUAUAGCUAAGGAGAGAUAUCUAGGACUGUAUCC
UGGAAUUGAG

Translation

Nucleotides 5 to 739: Frame 2; 245 aa

IQLLKAAYENFNSQDILLAPLLSAGIFGAKPLQSLQVCVQTVRTQVYIAVNDKALYEQVVMVDLNLKPRVEAPKQKEPPN
TEDSKTEESVQKPVDPVKPKIKACIDEVTTLEETKFLTNKILLFADINGKLYHDSQNMRLGEDMSFLEKDAPYVMGVDI
TSGDITCVVPSKKAGGTTEMLSRALKKVPVDEVITYTTPGQGCAGYTLEAKTALKKCSAFYVLPSEAPNAKEELIGTVS
WN

Alignment

replicase polyprotein lab Human coronavirus 229E

Identities = 48/202 (23%), Positives = 83/202 (41%), Gaps = 13/202 (6%)
Frame = +2

Query: 8 LLKAAAYENFNSQDILLAPLLSAGIFGAKPLQSLQVCVQTVRT---QVYIAVNDKALYEQV 178
+KA N Q L P+LS GIFG K SL+V + T +V++ + + +

Sbjct: 1371 LKAYNTINNEQGFPLTFLSCGIFGKLETSLEVLDVNCNTEKVKFVYTTDEVCVKVD 1430

Query: 179 VMVDLNLKPRVEAPKQKEPPNTEDESKTEESVQKPVDPVKPKIKACIDEVTTLEETK 358
+ L N++ +VE PKE P V KP V KAC +++ ++

Sbjct: 1431 FVSGLVNVQ-KVEQPKIEPKP-----VSVIKVAPKPYRVDGKESYFTEDLLCVAADKPI 1483

Query: 359 L--TNKLLLFADINGKLYHDSQNMRLG--EDMSFLEKDAP-----YMGVDVITSGDITC 508
+ T+ +L D L+ +L +D + K P + +G V+ +

Sbjct: 1484 VLFTDMLTLDDRGALDNLGSLVSAIKDCVDINKAIPSGNLKFDIGSVV----VYM 1539

Query: 509 VVIPSKKAGGTTEMLSRALKKV 574

+VPS+K + R +K+

Sbjct: 1540 CVVPSKKHLLDNVQVQTRKL 1561

EMC-2

UCGAGAUUUCaUcUUGAGCGGUGCAGGUUCUUUCACUUGACAACUAAAGAGUCUCUUAUCCUGCGGGAGGUU
AAGACUAAUAAAGUGUUCACACUUGUGGACACACUAAUCCACACACAGCUUGUGGUAUGUCUUAUGACAU
AUGGACAGCAGUUGUGUCCAAUACUUGUGGAGUGGUGUGAUGUUAACAAAUAACCCUUGUAAUACUAGA
GGGUAAGACUUUCUUGUACUACCUAGUGAUGACACACUACGUAUGAGUAGCUUUGAGUACUACCAUACUUCU
GAUGAGAGUUUCUUGUGAGGUACUUGUCUGCUUUAACACACAAAGAAUUGGAA

Translation

Nucleotide 2 to 349: Frame 2; 116 aa

RDFILTVQVLSLQKLSLSLREVKTIKVFITVDNTNLHTQLVDSMTYGGQFGPTYLDGADVTKIKPHVNHEGKTFEVLFP
SDTLRSEAFYYHTLDESFLGRYSALNHTKKWK

Alignment

> Bovine Coronavirus RNA-Dependent RNA polymerase

Identities = 25/90 (27%), Positives = 44/90 (48%)
Frame = +2

Query: 80 IKVFITVDNTNLHTQLVDSMTYGGQFGPTYLDGADVTKIKPHVNHEGKTFEVLPSDDTL 259

++ TVD N + V + ++G+ G + DG +VTK K +N++GK FF + +

Sbjct: 1565 VDILLTVGVNFTNRFVVGESFGKSLGNVFCDGVNVTKHEDCINYGKGVFTFDNLSE 1624

Query: 260 RSEAFYYHTLDESFLGRYSALNHTKKWK 349

+A D+ L Y + L + KW+

Sbjct: 1625 DLKAVRSSFNFDQKELLAYYNMLVNCSSKQ 1654

Fig. 2. Cont.

Alignment

> Murine Hepatitis Virus RNA-Dependent RNA polymerase

5 Identities = 48/126 (38%),

Query: 78 YIVNPVHTLSIHGDTYIELIYKAIQDGVTRDIISTDDCFANKHAGFDANFSGRG--SY 251
 +HP + + D +K I +GV RD+ TD CFANK FD W+ G Y
 Sbjct: 2859 WAINPTTVAHKSDMLPLYSFKVIDNGVLRDVSVDACFANKFQPCWYESTPTGLAY 2918

10 Query: 252 KNDKSPVVAALITREIGFTVFGIPGTVLRKNGDFLHFLPRFVSAGVNICITPTSLIEY 431
 +N K+CPVV A+ ++IG + +P TVLR LHF+ F+ CYTP I Y
 Sbjct: 2919 RNSKACPVVVAVIDQDIGHTLFWVPTVLR-YGFRVHLFITHAFATDSVQCITPHMKIPY 2977

15 Query: 432 SDFTAS 449
 +F S
 Sbjct: 2978 DNFTAS 2983

EMC-4

20 ACAGACACAACACUUCUGCUGUUCUGCAGAGUGGUUUUAGGAAAUGGCAUCCGUCAGGCAAGAUUGAA
 GGGUGCAGGUGUACAGUAAACUGUGGAAACUACAACUUAUUGGAUUGGUGGGAUACACAGUUAUCUGUC
 CAAGACAGUCUUAUUGCAGCAGCAGAACADGCUUAUUCUUAACUUAAGAAUUGUCUCUUAUCGCAAAUCCAA
 CCAUAGCUUUCUUGUUGCAGCAGGCAUUGUUAACUUGUUAUUGGCAUUCUUAUGCAAAUUGUCUGCUU
 AGGCUUAAAAGUGUAUACUUCUACCCUAGACACCCAGUUAUAAUUGUGCCGUAUACCAUUGGUGCAACAAU
 25 UUAUAGUUCUAGCAGUCUACAAGUGUACCAUUGGUGUUAUACAGUGGUGUUAUAGGACCUAAUCADUACCAU
 UAAAGGUUCUUCUUAUUGGAUUGUUGUAGUGUUGUUAUACUUAUAGUUAUUGGUGUGUCUUCUGC
 UUAUAGUACAUAUAGGAGCUUCCACAGGAGUACACGCGUGGUAUCUACAUGAAGGUAAAUUUAUUGGUCCAU
 UUGUGACAGACAAACUGCAGGCGAGGUACAGACACAACCAUACAUUAAUUGUUGGCAUUGGUGUGUA
 UGUGUGUUAUACAUGGUGUAU

30 Translation
 Nucleotides 2 to 679: Frame 2; 226 aa
 QTSITSIVLQSGFRMAFPSPGKVEGCMVQVTCGTTTLNGLWLDITVYCPRHVICTAEDMLNPYIEDLLIRKSNHSFLVQAG
 NVQLRVIGHSMQNCLLRLKRVDSNPRTPKYKRVRIQPGTFSVLACYNIGSPSGVYQCAMPNPNITKGSFLNGSCGSGVGFNI
 35 DYDCVSPCYMHMHELPTGVHAGTDLEGGFYGFVDRQTAQAGTDTTITLNVLAWLYAAVINGD

Alignment

RNA-directed RNA polymerase murine hepatitis virus

Identities = 122/222 (54%)

40 Query: 8 SITSIVLQSGFRMAFPSPGKVEGCMVQVTCGTTTLNGLWLDITVYCPRHVICTAEDMLNP 197
 S+T+ LQSG RM P+ KVE C+V VT G TINGLWLD VYCPRHVITC+ DM +P
 45 Sbjct: 3326 SVTTSFLQSGIVGVSPSTSKVEPCIVSVTYGNMTLNGWLDKRVYCPRHVICSADMTDP 3385

Query: 188 NYEDLLIRKSNHSFLVQAGNVQLRVIGHSMQNCLLRLKRVDSNPRTPKYKRVRIQPGTFS 367
 +Y +LL R+ +F Y+G + L V+ +M Q C L L V NP TPYK Y +P+P+P
 50 Sbjct: 3386 DYPNLCRVTTSSDFVMSGRMSLTVMSYMQGQQLVLTVLQNPNTPKYSEGVVKGGETP 3445

Query: 368 SVLACYNIGSPSGVYQCAMPNPNITKGSFLNGSCGSGVGFNI DYDCVSPCYMHMHELPTGVH 547
 +VLA YNG P G + +R +HTKGSFL GCGSGV+ + D V F YMR +EL TG H
 Sbjct: 3446 TVLAAYNGRPQAFHVTLRSSHTKGSFLGCGSGSGVGVLTGDSVRFYMHQLELSTGCH 3505

55 Query: 548 AGTDLEGGFYGFVDRQTAQAGTDTTITLNVLAWLYAAVING 673
 GTD G FYGP+ D Q Q D T T+NV+AWLYAA+ N
 Sbjct: 3506 TGTDFSGNIFYPYRDAQVQLPVQDYTTQTVNVVWAWLYAALEN 3547

EMC-5

60 Note that this sequence is not fully in frame.

AGUUGGAAAAGAGGCAUGCAGGCUAUGACCCAAAUGUACAACACAGGCAAGAUUCUGAGGA
 CAAGAGGGCAAAAAGUAAACUAGUGCUAUGCAAAACAAUGCUUUAUACUAGCUUUAUAGGAGGCUU
 GAUAUAGUAGCACUUAACAACAUUAUACAACAAUGCCGUGAUGGUUGUUGUCCACUACAACA
 UCAUACCAUAGACUACAGCAGCCAAACUAGGUUGUUGUCCUGAUUAUAGGUACCUACAACAA
 65 GAACACUUGUAGGUAAACACCUUUAUACAUAUGCAUCUGCACUCUGGGAAAUCCAGCAAGUU
 GUUGAGCGGAUAGCAUUGUUAACAUUGUGAUAUUAACAUGGACAAUUCACCAAAU
 UGGCUUGGCCCUUAUUGUUAACAGCUCUAAGAGCCAAACUCAGCUGUUAACUACAGAAUAA
 UGAACUGAGUCCAGUAGCAUACGACAGAUUGUCCUGUGCGGUGGUACACACAAACAGCUG
 UGUACUGAGUACAAUGCAGUCCUACUUAACAACAAUUGCAAGGGAGGUAGGUUUGUGUCUGG

Fig. 2. Cont.

CAUUAUCUAUCAGACCACCAAGAUCUCAA AUGGGCUGAUUCCUUAAGAGUGAUGGUACAGG
 UACAAUUAUACAGAACUGGAACCAUUGUAGGUUUGUUAACAGACACCAAAAGGGCCU
 AAAGUGAAAUAUCUUGUACUUAUCAAGGCUAAAACCAACUAAUAGAGGUUAUGGUGCUGGG
 CAGUUUAGCUGCUACAGUACGUCUUCAGGCUGGAAUUGCUA CAGAAUGUAACCGUCCAAUUA
 5 ACUGUGCUUUUCCUUCUGUGCUUUUUCAGUAGACCUGCUAAAGCAUAUaAAGGAUUAACUA
 GCAAGUGGAGGACAAACCAUACCAACACUGUGUGAAGAUUGUGUGUACACACACUGGUGACAG
 GACAGGCAUUAUCUGUUAACACAGAAAGCUAAACAGUAGGACCAAGAGUCCUUGUGUGGUCUUC
 AUGUUGUCUGUAUUGUAUGGCAUACCAUAGACCAUAAUCCUAAAGGAYUCUGUGACUUG
 AAAGGUAAGUACGUGCAAUAUACCUACCAUUGUGCUAAUGACCCAGUGGGUUUUAACAUUA
 10 GAAAACACAGUCUGUACCGUCUGCGGAUUGUGGAAAGGUAUUGCGUGUAUGUUGACCAACU
 CCGCGAACCCUUGAUGCAGUCUGCGGAUGCAUCAMCGUUUUUAAACCGGUGUUGCCGGUGUA
 GUGCAGCCCGUUCUACACCGUGCGGCACAGGCACUAGUAUCUGAUGUCGUCUACAGGGCUUU
 UGAUAUUUAACACGAAAAAGUUGCUGGUUUGCAAAGUCCUAAAAACUAA

15 *Translation 1*
 Nucleotide 3-701 ; 233 aa
 LEKMDQAMTQMYQARSEDKRAKVTSAMQTMFLTMLRKLDNDLNNIINNARDGCVPLNIPLTTAAKLMVV
 VPDYGTGYKNTCDGNTFTYASALWEIQQVVDADSKIVOLSEINMDSNENLAWPLIVTALRANSVKLQNNELSP
 VALRQMSCAAGTTQTACTDDNALAYNNKSGRFFVLALLSDHQDLKWARFPEKSDGTGTIYTELEPECFRFTDT
 20 PKGPKVKYLYFIKA

Translation 2

FKRVCGVSA-ARLTPCGTGTSTDVVYRAFDIYNEKVGAKFLK

25 *Alignment 1 of translation 1 sequence*RNA-Dependent RNA Polymerase; bovine coronavirus
 Identities = 181/413 (43%),

30 Query: 3 LEKMDQAMTQMYQARSEDKRAKVTSAMQTMFLTMLRKXXXXXXXXXXXXRGCVPLN 182
 LE+MAD A+T MYK+AR DK++KV SA+QTMFLF+H+RK GCVPLN
 Sbjct: 3985 LERMADLALINMYKEARINOKRSKVVSALQTMFLSMVRKLDNQLNLSLDNAKVGCVPLN 4044

35 Query: 183 IIPLTAAKLMVVVPDYGTGYKNTCDGNTFTYASALWEIQQVVDADSKIVOLSEINMDSN 362
 IP A L ++VED Y D TYA +WIQ + D+D QL+EI+ D +
 Sbjct: 4045 AIPSLAANTLTIIPDKSVYDQVNVNVVYIYAGNVWQIQTIQSDGTNRKQLEISDCH- 4103

40 Query: 363 NLAWPLIVTALRAN--SAVKLQNNELSPVALRQMSCAAGTTQTACTDDNALAYNNKSG 536
 WFL++A R N SA LQNNEL F L+ +G QT T YYNNS G
 Sbjct: 4104 ---WFLVIANRNEVSATVLQNNELMFAKLTQVNSGPGTQCNTPQ--CYNNNSNG 4158

45 Query: 537 RFVLALLSDHQDLKWARFPEKSDGTGTIYTELEPECFRFTDTPKGPKVKYLYFIKA+T* 716
 + V A+LSD LK+ + K DG + EL+PPC+F KG R+KYLXP+K T
 Sbjct: 4159 KIVYAILSDVGLRYTKILKDDG-NEFVLELDPFCKFTVQDVKGLKIKYLYFVKGNTLA 4217

50 Query: 717 EVNCNAV+LLQVPR- ----ENLQKYLPIQLCPFVLLQ*TLKHKIDYLSGGQPIT 878
 N V + RL E + LC SV + T L D+ G G PI
 Sbjct: 4218 R--GNVVLGISSTVRLOAGTATEYASNSSISLSCAFSVDPKRTYL----DFIQGGGTPIA 4271

55 Query: 879 NCVMKLCWTHGTGQAITVPEINMDDSEKGGASCLCYRCHIDHPNPKGKCDLKGKGVQI 1058
 NCVMKLC H GTC ATTV P+R +Q+S GGAS C+YCR ++HP+ G C L+GR+VQ+
 Sbjct: 4272 NCVMKLCRAAGTGMAITVXPDATTNQDSYGGASVCYICRANRVEPVDGLCKLRGKGVQ 4331

Query: 1059 PTTCANDPVGTPLRNTVTCVGNKGYGSCDCLREPLMQSADAKSLFNQFAV 1217
 F DPV + L + VC VCG W+ CSC + +QS D + FLNGF V
 55 Sbjct: 4332 PVG-IKDFVSYLTHDVQVCGFWRDGSCSCVS-TDITVQSKDIN-FLNGFV 4381

Alignment 2 of translation 2 sequence

RNA-directed RNA polymerase (ORF1) [murine hepatitis virus]

Identities = 24/44 (54%),

60 Query: 1199 FKRVCGVSA-ARLTPCGTGTSTDVVYRAFDIYNEKVGAKFLK 1327
 FKRV G S ARL EC +G TDV RAFD N AG + K
 65 Sbjct: 18 FKRVGTSVNARLVPCASGLDITDVLRAFIDICNARIGILYR 61

EMC-6

Translation 1

Translation 2

Alignment 1 of translation 1
replicase [bovine coronavirus]
Identities = 183/271 (67%).

ENS page 64

Fig. 2. Cont.

Sbjct: 6942 DGFTTYICHMIRDKLALGGVAIKITEFSWNAELYKLMGYFAFWTVFCNNANASSESEGL 7001

Query: 543 IGANYLGKPKKEIDGYTMHANYIFWRNTNPQLSSYSFLDMSKFFPKLRGTAVMSLKENQ 722
IG NYLGKPK +IDG MHANY+FWRN+ +YSLFDM+KFFPKL GTAV+L+ +Q

5 Sbjct: 7002 IGINYLGKPKVEIDGNVMHANYLFWRNSTVWNGGAYSLFDMARFELKLAGTAVINLRADQ 7061
IGINYLGKPKVEIDGNVMHANYLFWRNSTVWNGGAYSLFDMARFELKLAGTAVINLRADQ

Query: 723 INDMIYSLLEKGRLLIRENNRVVSSDILVN 815
INDM+YSLLEK+L+R+ N+ V D LVN

10 Sbjct: 7062 INDMVYSLLEKGRLLVRDNTKEVVFVGDSDLVN 7092
INDMVYSLLEKGRLLVRDNTKEVVFVGDSDLVN

Alignment 2 (Spike protein of coronavirus)
E2 glycoprotein precursor - murine hepatitis virus (strain JHM) contains spike glycoprotein

15 Identities = 199/798 (24%), Positives = 314/798 (39%), Gaps = 48/798 (6%)
Frame = +3

Query: 828 MFIFLLELTLTSGSDLDRCCTTDDVQAPNYTQHTSSM-----RGVYYP-DEI 965
+F+L L G D F +Q NY + +S RG YY D +
20 Sbjct: 2 LFVFILLPSCLCGYIGD----FRCIQTVNYNGNNAFSAFISTEADVSKRGTYTYLVRV 57
LFVFILLPSCLCGYIGD----FRCIQTVNYNGNNAFSAFISTEADVSKRGTYTYLVRV

Query: 966 FRSDTLTYLTQDLLEPF----YGNV--TGPHITINHTEGNE--VIPFKDGIYFAATE-KSNV 1118
+ + TL LT + P Y N+ TG +T+ T+ P + F DGI+ K+N

Sbjct: 58 YLNATLLLTG--YYPVGDGNYRNALGTNTLSLTWEKPPFLSEFNGDIFAKVQNLKNT 115
YLNATLLLTG--YYPVGDGNYRNALGTNTLSLTWEKPPFLSEFNGDIFAKVQNLKNT

25 Query: 1119 VRGW-----VFGSTMNKKKXXXXXXXXXXXXXKACRACFLCDNPFPAVSKPMGTQHT 1277
V GS N C + +C P+ KP

Sbjct: 116 PTGATSYFFPTIVIGSLFGNTSYTVVLEPYNNILMASVCTYITQCLPY-TECPK----- 167
PTGATSYFFPTIVIGSLFGNTSYTVVLEPYNNILMASVCTYITQCLPY-TECPK-----

30 Query: 1278 MIFDPAFNCTFEYISDAFSLDSEKSGNEKHLREFVFNKDGFLVY--KGYQPIDVVR 1448
N + + DV K R F F +LY + +G

Sbjct: 168 -----NTNGNRVIGFWHTDVKFPICLLK--RNFTFNVAFWLYFHEYQQSGTFFAYYA 218
-----NTNGNRVIGFWHTDVKFPICLLK--RNFTFNVAFWLYFHEYQQSGTFFAYYA

35 Query: 1449 DLFSGFNLTPIFKPLGGINITNERAILTAFSPAQDINGTSAAYFVGYLKPTFMFLKYD 1628
D PS L F + +G +T + + +P TA Y+V L T A Y+V L + +

Sbjct: 219 DKPSATTFEL---FSVYIGDILTQYFVLPFICTPTAG--STLAPLYWTVLLKQYLVNFN 273
DKPSATTFEL---FSVYIGDILTQYFVLPFICTPTAG--STLAPLYWTVLLKQYLVNFN

Query: 1629 ENGTTIDAVDCSQNPFLAEKCSVKSFEIDKGIYQISNFRVVPVSGDVR--FPNITNLCPFG 1805
E G IT AVDC + ++EKC +S G+Y S + V P G V R PN+ + C

40 Sbjct: 274 EKVITSAVDCASSYISEIKCTQSLPSTGVYDLGSGYTVQGVGVYRVRNPLED-CKIE 332
EKVITSAVDCASSYISEIKCTQSLPSTGVYDLGSGYTVQGVGVYRVRNPLED-CKIE

Query: 1806 EVFNATKFPVSVAWERKKISNCVADYSLVYNSTFFSTFKCVGSATKLNDLCSFNVYADS 1985
E A PS WER+ NC + S L + C + +K+ +CF +V D

Sbjct: 333 EWLTAQSVPSPLNWERRTFQNCNENLSSLLRYVQAESLCHNIDISKMGCFGSVSVDK 392
EWLTAQSVPSPLNWERRTFQNCNENLSSLLRYVQAESLCHNIDISKMGCFGSVSVDK

45 Query: 1986 FVVGDDVVRQIAPQGTGIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRLJHG 2165
F + + G +G + NYK+ C L ++ + T NYN R+G

Sbjct: 393 FALPFRSQIDLGICNSGELQTNAIDTAATSCQLYSLPKNNVT-INNYNFSNNRRY 451
FALPFRSQIDLGICNSGELQTNAIDTAATSCQLYSLPKNNVT-INNYNFSNNRRY

50 Query: 2166 KLRPFERDISNVFSPDGKCTPPALNCYWFPLNDYGFYTTTGIGYQPYRVVVSFELNA 2345
-----+ND R + + LIN

Sbjct: 452 -----FKVND-----RCQIFANILLG 468
-----FKVND-----RCQIFANILLG

55 Query: 2346 --PAVVGCPKL---STDLIKQCVNENFGLTGTGLTP--SKRQPPQFGRWSDFTD 2507
T C L +T+ CV ++ +G GV + +G DV+

Sbjct: 469 INSGITCSTDLQLENTEVATGVCVRYDLYGITGQGVKEVKADYNSWQALLYDVNGNLN 528
INSGITCSTDLQLENTEVATGVCVRYDLYGITGQGVKEVKADYNSWQALLYDVNGNLN

Query: 2508 SVRDPKTSILDISPCSPGGVSVITPGINASSEVAVLYQDVNCTOVSTAIHADQLTPMR 2687
RD T++ I C G VS + E A+LY++NC+ V T + + P

60 Sbjct: 529 GFRTDITNKTYTIRSCYSGRVSAAY--HKEAFEPALLYRNINCSYVFTNNISRENP-- 584
GFRTDITNKTYTIRSCYSGRVSAAY--HKEAFEPALLYRNINCSYVFTNNISRENP--

Query: 2688 IYSTGNVNFQTAGCLLGAEH--VDTSEYCDIPIGAGICASYHTVLSLR---STSQK--S 2846
N F + GC+ A++ C+ +GAG+C Y R ST + +

Sbjct: 585 -----NYFDSYLGCVNADNRTDEALFNCLRMGAGLCVDVYSKRRARRSVSTGYRLTT 638
-----NYFDSYLGCVNADNRTDEALFNCLRMGAGLCVDVYSKRRARRSVSTGYRLTT

65 Query: 2847 IVAYTMSGLADSSIAYSN-NTIAFTNFSISITTEVMPVSMARKTSVDCNMYIGDSTECA 3023
Y L DS + + IPTNF+I E + + K + +DC ++CGD+ +

Sbjct: 639 FEPYMPMLVNDVSQVSGGLYEMQLPTNFITIGHHEEFIQIRAPKVTIDCAARVCGDNAAAC 698
FEPYMPMLVNDVSQVSGGLYEMQLPTNFITIGHHEEFIQIRAPKVTIDCAARVCGDNAAAC

70 Query: 3024 NLLLQYGSFCTQINRALS 3077
NLLLQYGSFCTQINRALS

Fig. 2. Cont.

L++YGSFC +N L+

Sbjct: 699 OOLVEYGSFCNDVNAILN 716

RDG1 seq

[illegible]

Translation 1

Nucleotides 3 to 650: Frame 3; 216 aa
 QSLQXYVTVQQLIRXAEIIXXSANLAAATKMSCEVLGQSKRVDFCGKGYHLMSPFAAPHGVVFLHVTYVPSQERNFTTAPAIC
 HEGKAYVFPREGVVFVFNQTSWFTIQRFNFSPQIIITDNTFVSGNCDVIGIINNTVYDPLQPELDSFKEELDQYFKNHTSPD
 VDLGDISGINASVNNIOKEIDRLNEVAKNLNLDLDFEGLKGYEOYIKWPVWYV

Translation 2

Nucleotides 37 to 339: Frame 1; 101 aa
SGXLKXXLLILLLLKCLSVFLDNQKELTFVERATTLCPSHKQPRMVLSSYMRMCHPRRGTSPQRQFVMKAKHTSLVKV
FLCLMALIGLLHRGTSFLHK

Translation 3

Nucleotides 343 to 576: Frame 1: 78 aa
LLOTIHLSOEIVMSLLASLTTOFMILCNLSLTHSKKSWTSTSKI IHOMLILATFOALITLSSTEFKKILASMSRIKI

Alignment of translation 1

S glycoprotein [murine hepatitis virus]
Length = 1376

Identities = 86/218 (39%), Positives = 129/218 (59%), Gaps = 3/218 (1%)
Frame = +3

Query: 6 SLQTYVTQQLIRXAEIXXSANLAATKMSCEVLGQSKRVDFCGKGYHIMSFPQAAPHGVVF 185
+L Y+++QL I SA A K++ECV Q+ R++FCG G H++S Q AP+G+ F
Sbjct: 1105 ALNAYISKQLSDSTLIKESAAQAIKEVNECVKSOATTRINFCNGNHLISLVQNPAPGLYF 1164

Query: 186 LHVTVVPSQERNFTTAPAICHEG-KAYFPREGVVFVNGTSWFITQRNFFSPQIITDNTF 362
+H +YVP+ +P +C G + P+ G FV + W T +++ P+ IT N+
Sbjct: 1165 IHFSYVPTSTTTANVSPGLCISGDRGLAPKAGYFVQDDGEWKFTGSSYYYPETIDKNSV 1224

Query: 363 VSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTS--PDVDLGDISGINASVUNI 536
V +C V + + P L FKEELDK+FKN TS PD+ L D +N + +++
Sbjct: 1225 VMSSCSVNYTKAPEVLLNSSIPNLDPFKEELDKWFKNOTSIAPDLSL-DFEKLNVTFIDL 1283

Query: 537 QKEIDRLNEVAKNINLESILDLQELGKYEQYIKWPWYVW 650
E++R+ E K LNES I+L+E+G YE Y+KWPWYVW
Sbjct: 1284 SDEMNRIOEAIKKLNESYINLKEVGTYEMYKWPWYVW 1321

EMC-8

AGGCCAAACAGCGCCGACCCCAAGGUUACGCCAAUAUAUCUGCGUCUUGGUUCACAGCUCUCACUCAGCAUG
CGAAGGAGGACUCUAGUAUUCUUCUGACGCGCGGGCGUUCACUUAUACCAACCAUAGUGGUCCAGUAGACCAAAU
UGGCUAUCACCGAAGAUCCUACCGACAGUUGUCUGUGUGGACGCGCAARUAAGAAGACGACGCCGACGACG
UACUUCUUAUUAUCUUGAACGUGGCCAGAGAGUCUACUACUUCUACGCGGCUAACCAAGAAAGCAUGUAGUGG
UUGCAACUACGAGGGAGCCUGAUAUACACCAAGACCAUUAUGGACCCGCAACUAUAACAAAGUUGGCC

Translation

Nucleotides 1 to 363: Frame 1; 121 aa
 RPKQRRPQGLPNNTASWFTALTQHGEELRFRPGQGVPIINTNSGPDQIGYYRRATRVRGGDGKMKELSFRWYFYLLGTG
 PEASLPYGANKEGIVWVATEGALNTPKDHIGTRNPNNNXA

Fig. 2. Cont.

Alignment

nucleocapsid protein - bovine coronavirus (strain Mebus)

5 Identities = 55/129 (42%).

Query: 1 RPKQRRPOGLPNNTA-----SWETALTQHGK-EELRFRPGQGVPIINTNSGPDQIGIYYRR 162
+PKQ LP+ SWF+ +TQ K +E F GQGVPI + GY+ R
Sbjct: 44 QPKQTATSLPSSGNNVVPYYSWFSGITQFQKGKEFEFAGQGQVPIAPGVPATEAKGYWYR 103

Query: 163 ATRR-VRGGDGKMKELSPRWYFYYLGTGPEASLPYGANKEGIVWVATEGA-LNTPEDHIG 336
RR + DG +L PRWYFYYLGTGP A YG + +G+ WVA+ A +NTP D I
Sbjct: 104 HNRSEKTDAGNQROLLPRWYFYYLGTGPHAKDQGTIDIGFVFWASNOADNPAD-TL 166

Query: 337 TRNPNNNXA 363
R+P+++ A
Sbjct: 163 DRDPSSDEA 171

EMC-11: unknown sequence

[illegible]

Translation of putative open reading frames

```

45 >>out: 78 to 1: Frame -2      26 aa
    DFRSCHSYDHRLPYRYSYEEHCGMQ
>>out: 59 to 379: Frame 2      107 aa
    LWHLDLKSYPDGLDELGTDPEDYDQNNWTKHGSGALRELTRELNGAVTRYVDNNFCGPDGYFLDCIKDFLARAGKSMCTLS
    EQLDYIESKRGVYCCDRHEHEIAUWH
50 >>out: 283 to 89: Frame -1      65 aa
    IARACEKIFDAIKRVPIWATEIVVDIASDCTSIELTSFEFECTTAMLSPVFLVFIIFNGISAKLVT
>>out: 90 to 614: Frame 3      175 aa
    VTELALYELKIMNKTKTULSMAYVHNSVNLVSMEVQSGLAMSTTISVAQMGTLILASKIFSHARASQCALFENNLIITSRRE
    VSTAATVMSKMLSGFTEKSDKSGYENKQTFPEIKSAKILTITKRGMEQSLCFLTLCKSKSFNHVLKRKLRLVSWGVALCTLL
55 HLHRSVTCICLP
>>out: 204 to 124: Frame -2      27 aa
    RVTAPPLSRVSSRSAPLPCLVFQPCS
>>out: 312 to 208: Frame -2      35 aa
    SSCSERVHIDLPARARKSLMQSGVPSGGFKLLST
60 >>out: 485 to 258: Frame 3      76 aa
    EETQALGHSGPFESVNLGTGLNFBGCVLILVALIRALSEPRQFAHGHGSSRHLSSSTRCNQVVRKEKLTCPVRVRENL
>>out: 397 to 287: Frame -1      37 aa
    LLSRSVNEGNELMAVAVDTSLKLDVILKFGKSAH
>>out: 364 to 486: Frame 1      41 aa
65 NCLGSLSALIRATSTHESKLRVFKLITLSKGECFKACVSS
>>out: 490 to 614: Frame -1      30 aa
    VKRKKHKLWGIFLLKVSIFLALLISKGVWCS
>>out: 446 to 1483: Frame 2      346 aa

```

12/36

Fig. 2. Cont.

HFQKGNAPKLVFLPNSKVKVIQPRVEKKKTGEMGRIRSVYPVSPQECNNMHLSTIMKNCNHCDEASQTCDFLKATCEHC
GTENLVIEGPTCCGYLPINAVVMPCPAQDPEIGPEHSVADYVHNSNIETLRKGGRTACFGCGVAYVCCGNIRAYWVP
RASADIGSGHPTGTGDNVNE/LNEOLLEILSRERVNINIVGDFILNEEVAIXLAXFSARTSAPITDTIKSLDYKSFXTTIESC
GNKYTKGPKVKGAWNIQGGQSVITFLCGFSPQAAGVIRSIFARTLDAANHSIPDLQRAAVTILDIGEISQLRLVDAWVYT
5 SLLTNSVIIIMAYVTGGVQQT
>-out: 643 to 494: Frame -1 50 aa
SFIAMITFHQGRQVHIVITLLWRNCRVHRAYTPHETLSLFLTNWLNDFDF
>-out: 627 to 511: Frame -2 39 aa
LHFIVKVCILLHSCGDATGYTERIRPMKPSVFFFTSRG
10 >-out: 704 to 612: Frame -3 31 aa
LNFQCHNVHKWLESRTSAMKLRNDYISSR
>-out: 774 to 631: Frame -2 48 aa
QAGHGIFPTALVGRYHEVLSPTSITKFSVPQCSQVAFKSHVCHESQ
>-out: 826 to 737: Frame -1 30 aa
15 VVVLICNMLASNLMLVLRGTHWHEYSISR
>-out: 863 to 744: Frame -3 40 aa
SYLPCGVFEQLSGCCNLQHYAQVQSLGLDRQDMAFSLQH
>-out: 756 to 992: Frame 3 79 aa
KCHVLVPKTORLULSLIQTITQTLKLSAREVGLDVLEAVCLPMLAAISVPTGFLVLVLILAQAILALLVTMWRP
20 >-out: 952 to 830: Frame -1 41 aa
ANISTSTRNPVGTLLIAANIGKHTASKTSPTSLSAESSFN
>-out: 1056 to 922: Frame -2 45 aa
KSTTMLLTSRLSISRSSFKVSTLSPVMPVWPEPISALARGTQ
>-out: 1237 to 956: Frame -1 94 aa
25 SLLSNVSPSTFYGLSLGNFVITAGLNNGFRLVIRKTLVSNKGTCSRREXCCQXGNLFIQMKIANNVNVNTTQYVLKEILI
QGLHIVTNSASMA
>-out: 1140 to 1050: Frame -2 27 aa
SRLFVSIKALVEAEXDAKMMATSSFK
>-out: 1131 to 1205: Frame 3 25 aa
30 RVLITSLSKPLSPAVTIKLPRESP
>-out: 1410 to 1183: Frame -2 76 aa
TMASTRNDCEISPPSMVTPALCKSGIEWFAASSVRAKIDLITPAACEGKPHSGVKTDLCPCMFQAPPTGFLVTL
>-out: 1186 to 1311: Frame 1 42 aa
SYQGGKARKCLEHWTTEISFNTTWFVSLTGCWCYQINFAHT
35 >-out: 1283 to 1191: Frame -3 31 aa
HQQPVRENHTVVLKLSVVOCKSHLLRAFPW
>-out: 1248 to 1457: Frame 3 70 aa
HHCVVPHRLLVLSQFLRAHLMQTTQFLICKEQLSPYLMVFINSHYVLSTFWFILQTSPTVSLLWHM
>-out: 1381 to 1482: Frame 1 34 aa
40 TVITSRRRGLYFRPAHQQQHYIGICNNWSSCTTD

EMC12: unknown sequence

UGCUUGCUC AUGCUGAAGAGACAAGAAAAUUAUGCCUAUAUGCAUGGAUGGUUAGAGCCAU
AAUGGCCAACCAUCCAAGCUAAGUAUAAAGGAAUUAUAAUUAAGAGGGCAUCGUGUAGCUAU
45 GGUGUCCGAUUCUUCUUAUUAUACUAGUAAGAGCCUGUAGCUUCUAUUAUUAACGAAGCUGA
ACUCUCUAAAUGAGCCGCUUGUCACAAUGCCAAUUGGUUAUGUGACACAUUGGUUUUAUUCU
UGAAGAGGCGCGCGUGUAGGCUUCUCUUAUAAAGCUCUGCCGUAUGUGUCAUAUCAUCA
CCAGAUGCUGUUAUCAUAUUAUUGGAUACUCUCAUUCUGUCAUCAAAGACAUCUGAGGAGC
ACUUGUGAAGAAACAGUUCUUAUUGGCGUGUCUUAACAGAGAUUGGUCCUAUUCACAGACAGCG
50 UACAGAGUUAUGGUUGUAGA

Translation of putative open reading frames

>-out: 3 to 446: Frame 3 148 aa
LAHAETIRKMPICMDVRAVLAITQRYKGIQEGTVDYGVRRFFFTSKPVAALITKINSLNELVMPIGYVTHGFNL
55 EEARCMRSLKAPAVSVSSPDVNTTYNGYLTSSSKTSEEHFVETVSLAGSYRDSYSGQRTELGEV
>-out: 100 to 11: Frame -2 30 aa
ILILYLRMVMVAIMALTSMHIGINFLVSSA
>-out: 188 to 33: Frame -1 52 aa
RVQLRNRRSYRLFTSIKESDITVNDALNFNFSFILTDGCHYGSNIHAYRH
60 >-out: 64 to 159: Frame 1 32 aa
WQPSNVSIKELKFRASLTVMVSDSSEFILVKSL
>-out: 220 to 143: Frame -2 26 aa
PIGIVTSGSFREFSFVIIETGSLLV
>-out: 293 to 192: Frame -1 34 aa
HYGRSFKRTHTRSLFKIKTMCHITMNHCDKRLI
65 >-out: 397 to 224: Frame -2 58 aa
EPAKETVSTKCSVDVDEVRVFLYVTASGDDPTTAGALRERIRQAASSRLKPCVT
>-out: 229 to 288: Frame 1 20 aa

Fig. 2. Cont.

```
HMVLILKRIRAVCVLLKLLP
>-out: 292 to 372: Frame 1      27 aa
CQYHHQMLLLHMDTSLRHQRHLRSTL
>-out: 444 to 340: Frame -3    35 aa
5 QHLTLYAVLNRTNLCKSQPKKLFQSA PQMSLMTK
>-out: 416 to 351: Frame -1    22 aa
IGPISVRASQRNCFYKVLLRCL
>-out: 365 to 445: Frame 2     27 aa
10 GALCRNSFFGWLLQRLVLFRTAYRVRC
>-out: 376 to 435: Frame 1    20 aa
KQFLWLALTEIGFIQDSVQS
```

15

Figure 3.




Figure 4.

Comparison of N-termini of the S proteins of the group 2 coronaviruses

5


HCV	OC43	MFLILLISLPTAFAVIGDL-KCTTVSINDID
MHV	A59	MLFVFILFLPSCLGYGDF-RCIQLVNSNGA
BCV		MFLILLISLPMFAVIGDL-KCTTVSINDVD
SARS		MF-IFLLFL-TLTSG-SDLDRCTTFDDVQAP

10

Figure 5.



Figure 6.






Figure 7.

Figure 8 Detection of SCV in postmortem tissues of experimentally SCV infected cats and ferrets

Tissue	Cats				Ferrets			
	1	2	3	4	1	2	3	4
Trachea	+/	+/	+/	+/	+/	+/	+/	+/
	++	+	+	+	+	+	+	+
Lung	+/	+/	+/	+/	+/	+/	+/	+/
Tracheo-bronchial lymph node	-/-	+/	+/	-/-	+/	+/	+/	+/
Duodenum	-/-	+/	+/	+/	+/	+/	+/	+/
Jejunum	-/-	-/-	-/-	+/	-/-	+/	-/-	-/-
Ileum	-/-	+/	+/	-/-	-/-	+/	+/	-/-
Mesenteric lymph node	-/-	+/	-/-	-/-	+/	-/-	-/-	-/-
Kidney	-/-	+/	+/	-/-	+/	-/-	-/-	-/-
Urinary bladder	-/-	-/-	-/-	-/-	-/-	-/-	-/-	-/-
Peripheral blood	-/-	+/	-/-	-/-	-/-	-/-	-/-	-/-
mononuclear cells	-/-	-/-	-/-	-/-	-/-	-/-	-/-	-/-

* virus isolation/real time PCR results are depicted at day 4 p.i.

† died during the experiment.




Figure 9

Figure 10

1 atattagggt tttaactaac caggaaagc caaccaaacct qgactctgt tagatctgtt
 61 cctcaaacga accttaaaat ctgttgagct gtcctggcg tgcagtgcct ggcacctac
 121 gcaatataa caataataa tttaactgt gttgacaaga aacagataac tgcctcotc
 181 tctgcagact gctacaggtt tgcctcgtc tgcagtgat catcagata cctagcttct
 241 gctcgaggt gaccgaagc taagatgag acctgttgc ttggtgtca cgaataaaca
 301 cagctccaac taagtgtcc tgccttcag gcttagaac tgcctagtc tggcttcggg
 361 gactctgtg aagagccct atcgaggca cgtgacacg caaaaatg gacttgggt
 421 ctatgagc ttgaaaaag ctaactgcc caagctaac agccctgtt gttcattaa
 481 gttctgtg ccttaagcac caatcacgc cacaagtgc ttgagctggg tgcagaatg
 541 gacggcattc agtaaggctg tagcggtata acactggag tactgtgtgc acatggggc
 601 gaacaccaca ttgataccg caatgtctt ctctgaaga acggtaataa gggagccgg
 661 gtcatagct atggcatcga cctaaagct tatgactag gtcagaggtc tggcactgat
 721 cccattgaag attatgaaca aaactggac actaagctat gtaggggct acctgtgaa
 781 ctactcgtg agctcaatg aggtcagtc actcgtatg tgcacaaca ttctgtggc
 841 ctactcgtg acctcttga ttctcaaaa gatttctcg cagcggcgg caagtcaatg
 901 tgaactctt ccgaacaat tgaatacat ggtctgaga gagggtgcta ctgcgcct
 961 aaccatgag atgaataag ctgttcaat ggcgctctg atagagcta cggacacag
 1021 acccctctg aaataagag tgcagaata ttgacaatt tcaaggga atgccaaag
 1081 ttgtgttct ctttaactc aaagtcaa gttcttaac cagtggtga aagaaaaag
 1141 actgaggtt teatggcgc tatagctct gttacactg ttgactctc acagaggtg
 1201 acaatagc actgtatag cttgtgaaa caatgtgaa catgtggca ctgaattt agttatgaa
 1261 acgtgcact ttctgaagc caatgtgaa cacttcaat actgtctgag tgaatatgc atgtctgac
 1321 ggcactaca catgtggtg actcactac atgtctgag tgaatatgc atgtctgac
 1381 atgaaactc gactgggaa gggagtagg actagattt ttgagagctg tgtttggc
 1441 atgttgtct gctataata ggtgcctac tgcgtctctc ttgagagctg tgtttggc
 1501 tatgttgtc gctataata ggtgcctac tgcgtctctc ttgagagctg tgtttggc
 1561 taaggcata atgacatac tgggcaat cgggagact tgaatgagc tctcttggc
 1621 atactgagt ttactcaac atgtggcg atttcaatt gaatgaag cactataag
 1681 gtgtatca ttgggcact ttctcgtt tctacaagt ccttattga cactataag
 1741 acttggtt caagctctt caaacact gttgagctc ggggtacta taagtaca
 1801 agggaaagc cagcaaaag tcttggaaac atttgacaac agagatcagt tttaacca
 1861 gctgtgtgt ttccctaca ggcgtggtt gttatcagt caattttc ggcgaact
 1921 gttgcagca accacacat cctgatttg caaagagcag ctgtccact acgttggt
 1981 attctgac agtcaatc ttgttcgac gccatggtt atactcaga cctctcac
 2041 acaggtgca ttatttgg atagtgaat ggtgtgttg tacaacagc tctcagtg
 2101 tgtctaatc tttagggac tactgtgaa aaactcagg ctactctga atgattgag
 2161 ggaacata gtgcagact tgaattctc aagatggtt gggagattct caatttctc

Fig. 10. Cont

2221 attcaacaggt ttttttaact cgttcaagggt caaatcacagg ttgtcttcaga taactatcaag
 2222 gatttgtgttaa aatgtgttcaat tgatgttggtt acaacaggcac togaattgtg tactgtatcaa
 2231 tgcactatctat cgttcgcctcaa ttgtcgatca ctcaactttag gtgaagtact catctgtctcaa
 2241 agcaaggagc tttaactgcga ttgtatcaggt ggcaacaggag cctgtgaact catctgtctcaa
 2461 cttaaaggagc caaaaagaat aacactttct gaagtgattt cagatgcac agtacttaacc
 2521 tttagggagg ttgtttctcaa gaacgttgaa cttgaagacat cgtctgtatg cgtctgtatg
 2531 ttcaaaaatg gagctatggt ttgcacacca ttgtgtftaa atgtgcctat cgtctgtatg
 2541 attcaaaaatg gaagaacaata ctgcgcattg tctctgtatt tctcgtctac acaaatgttc
 2641 ttctctcttca aaggggtgtg accaatftaa ggtgttaact ttggagaga tactgtttgg
 2761 gactgtcaag ttctacaaga ttatgaatc attttggc ttgtatgaag ttgtgacaaa
 2821 tgcattgttg aagatgtctc tttctaacat ttgataatcg agttactggt tactgttttt
 2891 gcatgtgttg taagaagagc ttgtttgaag ttgataatcg agttactggt tactgttttt
 2941 acaatggtta ttgtatttga ttgttttgaag ttgtttgaag actttacaac tactgttttt
 3001 ggtgaagaata actttttcta agttttgtat ttgttttctt acccttcaga ttgagaagaa
 3061 gaggacatag cagaatgttga ggagaagaa attgtatgaa ccttgaaaca ttgatacgtt
 3121 aagagagatg attatacaag ttactctctg gaattgtgtg cctcagctga aacagtttga
 3181 ttgtagaag agaaagaaga agactggctg tgatatacta ctgagaatc agagatttga
 3241 cagaacacg taactatccc taagaagca gttcaatcagt ttactgttta tttaaaactt
 3301 actgcacatg ttgcattcaa atgtgtgtgac atcgttaagg aggcacaaag tgcataactct
 3361 atgttgtatg taactgtctg taactatcac atgaaacatg ttgtgtgtgt agcaggttga
 3421 ctcaacagg caacctatgtg tgcatacga aagagagatg atgtgtgtgt taagagttga
 3481 ggcctcttta cagtagaggg gctgtgttgg cctttgtggc ataactttgc taagaaagt
 3541 ctgcattgtg ttggacctcaa cctaaatggca ggtgaggaca tccagttctc taagagagca
 3601 tatgaanaat tcaattcaca ggaactctta ctgcaacat ttgtgtcagc aggcataatt
 3661 gggtcaaac caactcagtc tttaacatg ttgtgtcaga cggttgtgac acagtttatt
 3721 attgcattga atgacaagc tctttatgag caggtttgca ttgattatct ttcaaacctg
 3781 agccttagag ttgaagcacc taacaaggag gagccaccaa acacagaaga ttccaaaact
 3841 ggagagaat ctgtgttaca gaagctgttc gatgtgaagc caaaaattaa ggcctgcatt
 3901 gatgagttta ccaacacact ggaagaact agttttctta ccaataagt actctgtttt
 3961 gctgatatac atgttaagct ttaccatgat tctcagaaca ttgttagagg ttgaagatg
 4021 tttttctcag atgaagatgc accattcatg gtatgtgatg ttatcaatg ttgtgatatc
 4081 atttgtgttg taactccctc caaaaaggtt gttgtcacta ctgagatgct ctcaagagct
 4141 ttgaagaag ttccatttga ttgattata accagttacc ctgacaagg atgtgtggt
 4201 tatcaactg agaaagctaa gactgtcttt agaaatftga actgtcat ttgaattgaa
 4261 ccttcagag caactaatg taagaagaag attctagaa tcttatcctg taattgtaca
 4321 gaatgtgtg ctatgtctga agacaaga aatataatc ctatagcat ggaattgaga
 4381 gccatgttg caacctoca acgtaaatg aaagaatta aacttgaat ggaattgaga
 4441 gcatatgttg tccgattctt attttact agtaagagc ttgtatgctt tattcatagc
 4501 agctgaact ccttaaatg gccgttctg acaatgcaa ttgtttatgt taactatagc
 4561 tttaacttgg aagagctgct gcgtgtatg cgtttcttta agcctctgc cgtatgtca
 4621 gttatctaac cagatgtgtg taactaatat aatgtataac tccctctgc atcaagaaga

Fig. 10. Cont.

4681 tctgagagc aattgtaga aacagtttct ttgcttgct cttacagaga ttgctctat
 4741 tccagagac gtacagagt aggtgtgaa ttctttaagc gtgtgacaa aattgtgtac
 4801 caagcttc aggcocccgt gaggttcat cttgacgttg aggtcttctc attgtgacaa
 4861 ctaaaagtcg tctctaccc cgggttgctt agcatatgaa aagtcttcc aactgtgac
 4921 aacacaaac tccacacaa cgttgtgctt atgtctatga ccatgtgaca cgaatttggc
 4981 ccaactaat tgaatgtgc ttgtgttaca aaataaasc ctaatgaaa tcatgaggt
 5041 agactctct ttgtactac ttgtgtgac agcatagta gtgaagctt cgaftacac
 5101 catcactct atgagctt ttgtgtgag tcaatgtcg ctttaacca caacaagaa
 5161 tggaaattc ctaagttgg ttgttlaact tcaataaat ggcctgata caattgtat
 5221 ttgtctagtg ttatttag acttcaaac cttgaagta aattcaatg accagaactt
 5281 caagcggct attatagc cctgtgctgt gctgtgta actttgtc actcaactc
 5341 gcttacaagt ataaactgt tggcgagctt ggtgatgca gagaactat gacactctt
 5401 ctacagatg caaatttgg aatctgaag cgaattctta atgtgttgg taacaattgt
 5461 ggtcagaata ctaactactt accgggtgtg gaagcttga tptaaaggg tactctact
 5521 tatgataat ttaagacagc ttgttcaatt ccaigtgtg tgggtctgga tgotacaaa
 5581 tatctagtac aacaagctc ttcttttgt atgatgtcg caacacttcg tgaatataa
 5641 ttacagcaag gtacattct atgtcgcaat gattacaact gtaactataa gctgttcat
 5701 taactctata taactgtcaa ggaagaccto tatgtatg agggactata ctttaaaa
 5761 atgtcagagt acaagagacc agtactgat gttttctg agynaactc tttaactaca
 5821 acctcaagc cgtgtgtcta taactgat cgaattactt accagagat tgaacaaaa
 5881 ttgatgggtt attataaaaa ggaatagtct tactaaag agcagctat agacttga
 5941 ccaactcaac caatacaaa ttgagagctt gataattca aactcaatg ttctaacaa
 6001 aaatttggct atgattttaa tcaaatgaca gcttcaaa agcagcttc acgagcta
 6061 tctgtacat ttctccaga ttctaagtc ttgtatggg caatgttgg gacatacat
 6121 tctgagactt tcaagaagc gttcaaatb atgtcaagc caatgttgg gacatacat
 6181 aaggtacaa ccaagacac ttgaacaa aacacttgggt gtttaagttg tcttggagt
 6241 acaagocac tagacttct aattctatt gaaattctgg cagtgaaga caacaagga
 6301 atggacaatc ttgttgtga agtcaaaa ccaactctg aagaatgat ggaataatcct
 6361 accataaga aggaagat atgtgtgtna gttgaaata cgaatgtgt aggaatgtc
 6421 atactaaac catcagata aggtgtgana ttgaacaa gattagcta tgaatgtctt
 6481 atgtgtgct ttatgaaat tgaagcaat accataaga aactaatga gtttcaact
 6541 gctttagtt taagaact tgaacactt ggtactctg caattaatg tctctctg
 6601 agfaaaatt ttgtttatgt tgaacactt ttggagcaag cagcaattac aacataaat
 6661 tggcgttaag gattgacat accgtgttctt acaattata gcaattagt gttacatta
 6721 ttctcaat ttgtactct tactaaagt acaattota tcaattagc ttcaactct
 6781 acaatttgg tcaaaatgt ttgtaaat ttgttaaat tatgttga tgcgcgaat
 6841 aatttggta agaacocaa atttccaaa ttgtocaaa tgcgtatgt gctattgtg
 6901 ttatgatt gcttacttg ttaactgt tgaactgtg cttttgtgt actattatc
 6961 aatttggg cctctctta ttgaaatgg gttagaagt ttatctaa ttgtctaac
 7021 gttactata ttgattttg ttgaagttct ttcttcca gcaattgtt asgtgata
 7081 gactcctct attctacc agctctgaa accattcag ttacgatttc atgtacaa

Fig. 10. Cont.

7141 ctacagctga caatttttagg tctggccgct gactgggttt tggcatatat atgtttcaaa
 7201 aaactttttt attatttagg tcttccagct aaatcaagc tttctttgg ctattttgt
 7261 acattttca taagcaattc tggctcatg tggttataa ttgatttgg acaattgttc
 7321 ccgtttctg caatgcttag tagtcaatc tttttgctt ctcttcta cataagga
 7381 agtcattgc atactatga gtttcaacc tttctgctt gcatgatgg ctatagcgc
 7441 attctggcca cacgcttga gtttcaacc tttctgctt gcatgatgg ctatagcgc
 7501 gttcattgaa atgagctggg tggctctgc aagtatcaa atggaaag atctttctat
 7561 gacacattt gacgttggg taacttcat agtgaagc ttgctctga ttgttcact
 7621 cagtttaaaa ggcacatcaa cctctagc cagtcacgc atattgttga ttgttctt
 7681 ttgaaattg ggcacatcaa cctctagc cagtcacgc atattgttga ttgttctt
 7741 catccgctt ccacttttgc catctttag aatttgagc gtcaaaagc atagagaga
 7801 ctgcctatta agttcatagt tttgtatgg aagtcacaa gtacagagtc tggttctaa
 7861 tctgtctatg ttgtttacag tcatgtgat tgcacacaa tctgttggc tgcacaaagt
 7921 ctgttatcag agttttcaga tagtactga gttccacta ttctgttgc tgcacaaagt
 7981 gacacattt cagtcacatt tagtttctc atggaaaac ttaaggaact tgttgtaca
 8041 gctcacagcg agtgaacaa ggttgtagct ttgatggg tccctttac attcgttca
 8101 gctcacagcg agtgaacaa ggttgtagct ttgatggg tccctttac attcgttca
 8161 aaactttcac atctcttga cttagagtg acagtgaca gttgtaacaa ttctatgct
 8221 acctataaa agtttgaaa catgacgcc agagatctg ggcgatgat tgcagttaat
 8281 gaaagtcata tcaatgcca agtgaacaa agtcaaatg ttctactcat tgcagttaat
 8341 aaagtcata tctttttac tgcacagct gttcaacaa tctgatgic tgcagaaga
 8401 atcaacatac ctttttagct acatttgcct acaactagac agttgttcaa tgcataact
 8461 actaaattc cactcaagg ttgtaagatt tttagtactt gtttaaaat tatgottaag
 8521 gctcaattc ttgcgtctt ttgtcatg ttgtttata tcttatgac agtacaata
 8581 ttgcaattc agtatgtta cacaatgaa catcttggtt acaagcact tcaagatggt
 8641 gctacatgc aacacattc tactgatgt gtttttgcaa ataaactgc tggtttgc
 8701 gctatgtta gcaagctgg ttgttcatc aaaaatgaca aaactgccc tggatgact
 8761 gctacattc caagagatg ttgtttcaa gtgcctgct taccggtac tggatgaga
 8821 gcaatcatg gtagctctt gattttca cctgtggt ttatgtgt tggcaaat
 8881 gttcacacac cttcaactc catgtgat agtgattg ctgctctg ttggttctt
 8941 tgcgtgagt gtacaattt taagatgct atggcaaac ctggcctta ttgtttgac
 9001 actaatggc tagaggttc talttctat agtagcttc gtccaagac tggttatgg
 9061 ctctgatg gttccatcat acggtttct aacactac tggaggttc tgttagaga
 9121 gtaacaact ttgatctga gtaactgaga catgtgcat ggaaggtc agaaaggtc
 9181 attgctat ctacacgtg tagatgggtt cttaaatg agctataag agctataa
 9241 gagttttct ggtgtttga tgcataaat cctaagta aactttac tctcttgg
 9301 caactgtgt gtcgtttga tgcctgct tcaagtgg ttggtttgg tagtaca
 9361 ttggtgactt gtcgttga cactttat aattgcag gttgtttgg tagtaca
 9421 catgtgtgt cgtctaagc caattttt ttatgtct tcaactact cgtgttga
 9481 caggttaca ctttctacc ggaagtac tcaagcttc actgtact gactgtga
 9541 ttcaacaatg atgtttcat ttgcatggt ttccttatt

Fig. 10. Cont.

9601 gtgcgtttttt ggataacagc aatctatgta tctgtatatt ctctgaagca ctgccattgg
 9661 tctcttaaca acatctctag gaaagagtc atgttaatg gactacatt tagtaoctic
 9721 gaggagactg ctttggtac cttttgttc aacaggaaa tgttaactaa atgtctagc
 9781 gagacactgt tgcacttac aactataac agtatcttg ctctataaa caagtacag
 9841 tattcttagt gactcttaga taacacagc tatgtgtgag cagcttgctg ccaattagca
 9901 aggtctctaa atgacttaga taactcaggt gctgtatgc tctaccaacc acacagaca
 9961 tcaatcaact ctgtgtctt cgaagtctt tttagaataa tgcattccc gtcagcaaa
 10021 gttgaaggtt gcatgtgaca agtaacctgt tgaactaca cttttaatgg atgttggtt
 10081 gatgaacag tatactgcc agtcaatcc atttgcasg cagaacat gcttaoctic
 10141 acatagaag atctgtcat tgcataatc aacctatgt tcttgtca gcttgcaat
 10201 gttcaactc ctgttatgg ccattatgt caaaattgc tcttagctg taagttrgt
 10261 actctcaacc ctaagacacc caagtataa ttctocgta tccaactgt tcaaacatt
 10321 tcagtctag catgtcaaa tggttcaaca tctgtgitt atcadtgic catgaaact
 10381 aatcatacca ttaagggttc ttcttaat ggaatctgt gtatgttgg tttagaact
 10441 gattatgatt gctgtgtttt ctgtatag catcatatg accttccaa aactgaac
 10501 gctgtactg acttagaag taactctat gctcatctg ttgacagaa aactgaac
 10561 gctgcaggta cagacacac cataacatta aatgitttg calggcgra tgtgtgtgt
 10621 atcaatggg atagtggtt tcttaaga ttcaacacba ctttgaaga cttgaactt
 10681 ttgcaatga agtcaacba tgaactcttg acaacagtc atgttgcat atggaaact
 10741 cttctgttc aacaggaaat tgcctctta gatatagt ctcortgaa agsgtgrtg
 10801 cagataggta tgaattgta tactctact ggtagacba tttagaaga tsggtttaca
 10861 ccaattgag ttgttagaca atgctctgt gtaacctcc aagbtaagt tsggtttaca
 10921 gtaagggca ctaactcat gctctctgt attacttga catctact gactttgtt
 10981 caaagtacac agtgtcatc gttttcttt cttragaaga atgctttct gccattact
 11041 cttgttatta tggcaatgc tctgttaac tctctbaca acaatgctt gttcttact
 11101 cttgtactg ggtgtagtc tgcgtgag tatcatgca tgccttgat gttcttact
 11161 cttgtactg ggtgtagtc tgcgtgag tatcatgca tgccttgat gttcttact
 11221 gtttatgca ttaagatgt tgrtatgca agatgctt tsgtttgat gttcttact
 11281 acagctgca cttgttata tgaatgca tgaatgctt tsgtttgat gttcttact
 11341 acactgtta acaagtcca atggtatc agatgctt tsgtttgat gttcttact
 11401 ttgatttat cttgaacctc taactatc agatgctt tsgtttgat gttcttact
 11461 agagctatg tctgtgtgt tttgtgtgt tttgtgtgt tttgtgtgt tttgtgtgt
 11521 cttctgtta tcaactatg tttgtgtgt tttgtgtgt tttgtgtgt tttgtgtgt
 11581 cttctgtta tcaactatg tttgtgtgt tttgtgtgt tttgtgtgt tttgtgtgt
 11641 tcaacaag aatttggta tgaactcc cagggtctt tttgtgtgt tttgtgtgt
 11701 gattcttca agttcaaat tgaactcc cagggtctt tttgtgtgt tttgtgtgt
 11761 gctactgac gttcaaat tgaactcc cagggtctt tttgtgtgt tttgtgtgt
 11821 cttcaaac cagagatga gtaactct aatttggg cacaatgt acaactcac
 11881 aagatattc ttcttgcaa agacaact gaagcttgc agaatgtt tctctttg
 11941 tctgtttgc tatcatgca ggtgtgta gacattata ggtgtgga gaaatgct
 12001 gatacttca ggtcttct tgaactta atcatgct

Fig 10. Cont.

12061 gcttatgcca ctgcacagga ggcctatgag caggcgtgag ctaatgttga ttctgaagtc
 12121 gtctccaaac agttaangaa attcttgaat ctggctaaat ctgagtttga ccgtgatgct
 12181 gcaatgcacac gcaacttggga aagatagcca actcaggeta tgaccacatg gtacaacacg
 12241 caagatgtty agnacaagga ggcnaaagta actagtgcta tgcaaacat gtctctcaat
 12301 attcttgaga acctgtata ttgatcactt acaacattta tcaacaatgc gctgatgggt
 12361 tttgtttcca tcacatcatc acctatgact acagcagcca aactatgtt ttgtttccct
 12421 gattatggta ctcaacagaa ccctgttgat gttacaact ttacattatg atctgcactc
 12481 tggnaatgcc agcaagtgtt tgaatgggat agcaagtgtt ttcaatttag tgaattaac
 12541 attgcaaat ccaccaaat ttgactggct gcttggcct ctatgtta cagctctaa agccaatac
 12601 gctgttaaac tacagaataa tgaactggct cactatgac tagctagac agccaatca
 12661 gctgtgtacca caacaacgc ttgatctgat gcaaatgac tagctagac agccaatca
 12721 ttccctaaag ctgattgtct ggcattgtat tgcactacta tcaagccac agttctccaa atgggctaga
 12781 gttacagaca gctgaatgc agctaacatt tacaagacac agttctccaa atgggctaga
 12841 gttacagaca gctgaatgc agctaacatt tacaagacac agttctccaa atgggctaga
 12901 aactcaata gagtgatgtt gctggcaggt ttactgtgta cgttactcaa aggtcttaac
 12961 aatgtacag aagtacttgc caattcaat ttgttttctc ttgtgtcttt tgaagtgag
 13021 ccgtctaaag catataaga ttactcgaca agtggagac aaacaaacac caactgtgtg
 13081 agatgttgtt gtacacacac tggctacaga caggaatta ctgttaacac agaatctaac
 13141 atggaccaag agtcccttgg tggctgcac ctgtgctta ttgtctctgt attgtatg ccaactgac
 13201 catccaatc ctacaagatt ctgtgctta ttgtctctgt attgtatg ccaactgac
 13261 ttgtctaatc acccaatgtt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13321 tggaaagtt ttgtctctgt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13381 gcaacaagt ttgtctctgt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13441 caggcaatg tactgtatgc gttctctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13501 gtttttgaag attctctctgt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13561 attatgaa attctctctgt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13621 agcaattta tactctctgt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13681 ttggagtaga ttgtctctgt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13741 tggcgtatg ttgtctctgt ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13801 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13861 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13921 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 13981 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14041 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14101 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14161 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14221 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14281 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14341 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14401 attctctgt caatacatc ttgtctctgt ttgtctctgt ttgtctctgt attgtatg ccaactgac
 14461 cgcctctctg ttccaagaa ctttttgtgt tactgtatg ttcaagtaga tcaagtaga cagcagctt

Fig. 10. Cont.

14521 atgggaattt attgctagat aaagcaacta catgctttc agtagctga ctaaaaaa
 14581 atgttgcttt taaaactgc aacacoggtt attttaaa agactttat gacttgcct
 14641 tgcctaaag tctctttaag gaagaaagt cgtttgaact aaaaacttc tctttgcct
 14701 agatgaagaa cgtcgtctac agtataatg actatatac ttataactg ccacaaatg
 14761 ggtatacag acaactccta tctcatatg agtttgta taataactt tgcgttacy
 14821 atgttgctgc tattaactc aacaaagtaa tctttaacc tctggataaa tctgtgggt
 14881 tccattttaa taaaagggtt aagctagac ttatattga cctaaagat tctggagtc
 14941 aagatgaact tcttcgctt acttagctc atttagctg cctaatcact caaatgaatc
 15001 ttaagtatc aattatgca aagaatagag cgcgcacg agctgtgtc totatctga
 15061 gcaatgac caataagaa ttctatcaga aattattgaa gccaatagcc gccactadag
 15121 gagctactg ggaatttga acaagcaagt ttacgtgtg gccaataat atgttaaaa
 15181 cgtttacaa tgaatgagaa actccacacc ttatgggtg gattatoca aaatgaca
 15241 gacactgaa ctatctgctt aggtataag cctctctgt tottgctgc aaataaaca
 15301 ctatctgtgaa ctatctctac cgtttctaca ggttagctaa cgaagtgcg caagtattaa
 15361 ctgagatgtt caagtggcc atgttaaac aggtggaaca tcatcoggt
 15421 atgataaac tctttatgct tottaagctt tcaaatgg tcaagctgtt acagccaatg
 15481 taaatgaact tctttatgct gatggtaata agatagctga caagtatgc cgaactctac
 15541 aacacagct ctatgaggt cctatagaa ataggatgt tgatcagaa ttctggatg
 15601 agttttatgc ttactcgtt aaacattct coactgatg tcttctgat gatgcoggt
 15661 agttatgaa cagtaactat ggcgtcaag gtttagtag tagcataag acctttaag
 15721 acattctta tctacaaat aatgtgtca tgcctgagc aaaaattgg actttaag
 15781 acattctta agaacctcac gaatttgcct ccaagatc atctagatt aaaaagtag
 15841 atgtttactg gtaactcctt taccacgac tctatgata aagtttgcg gctgtttg
 15901 tggatgatct tgcataaca gatggcac ttatgata aagtttgcg tcactgcta
 15961 ttgtgctcta ccaacttaca aaactccta atcaggata tgcctatgt tctactgtt
 16021 attacaata cattaagaag ttacatgat agcttactg ccaatgttg gacatgtat
 16081 cgttaatgt aactaatgt acaactcac ggtactgga acctagitt tatgaggcta
 16141 gtaacacac aactacagtc ttgcaggtg taggtcttg tctattgc aatcacaga
 16201 ctctactgag ttgggtgac ttgtattgga gaaatcct atgttgcaag tgcgtctatg
 16261 acctgttat ttcaactaca caaaaatag tctgtctgt taatccctat gtttcaatg
 16321 cccaggtgt ttgatcact gatggacac aactgtatc aggaagtatg agctaattt
 16381 caagtaaca taagctccc atagtttgc ctatattgc cttcaatgc gtttttgtt
 16441 tacaacaaa caatgtgtg ggaactgaca atgtcactga cttcaatgc atgaacaat
 16501 gttatggac taatgttgc gaaacgctc aagacacty aggaacatt taagtctga agactcaag
 16561 ttcttgtagc aagaactcct tctgcagag attgcaact ttactgtgag gttgaaaac
 16621 ccaagtacac gaagtactc tctgcagag attgcaact ttactgtgta cgtgttaact aaaaatgca
 16681 ctgagccacc attgagacg aactatgct ttactgtgta cgtgttaact aaaaatgca
 16741 aatgacagat tggagatc actttgaa aagtgacta ttgtgtgact tctgtgtaca
 16801 gaggtaact gacatacag ttgaattg gttgattact ttgtgtgact tctgtgtaca
 16861 tatgcaact tagtgaact actctatgc caaagaca ctatgaga atctatgct
 16921 tgaaccacac actcaacatc tcatgatgt ttctatgaa ttgtgaact tatcaaaag

Fig. 10. Cont.

16981 tggcgatgca aagtaactct acactccaag gaccactgg tactgtgaag agtcaatttg
 17041 caactgagct tgcctctat taccactcg ctccatagt gtatcgga tgcctcatg
 17101 cagctgtgca tgcctatgt gaagaagcat taaatatit gccatagat aatgtcagt
 17161 gactcatacc tggcgtgcg cgggtagagt gtttgttaa attcaaatg aatcaaac
 17221 tagaacagta tttttctag actctaatg ctctgcaga aacacagctg aatcaaac
 17281 tctttgataa taactctatg actctaatg actctgagc tctgtccat gctagacttc
 17341 tgcgaacaa cacactctat attcgcatc ctgtccaat accagccccc ggcacttc
 17401 tgcctaaag cacactaga cagaagatc ttactcag ggcagactt atgaaacaa
 17461 tgcctcaga catgttcct ggaacttc gcoctgtcc tctgaaatt gtgaacatg
 17521 tgaactgtt atttatgct ctatgaac aagcacaaa ggtaaatga gctcaatgt
 17581 taaatgctt ctacaaggt ttatgacac atgatgttc attgcaatc aacagacct
 17641 aaataggtt ttatgacac gcaatcccg tgggaaaaa gctgtttta
 17701 tctcaacta taatccag acgtgttag actatgat attccacaa actactgaa
 17761 ctgtgtatc atccaggt tgcgaatg actatgat attccacaa actactgaa
 17821 cagcaactc tgcgaaggt aacgttca atgtgctat cacaggcca aaattgca
 17881 ttttgagat aatgtctt agaatcttc atgcaaat gcaatttaa actctagaa
 17941 taccacgtg caatgtgtt aactcaag cagaaatg aactggact ttttagaat
 18001 gtagaagat catctaggt tctcatcca caccagacc tacacacct agcgtgata
 18061 gactgaaga ttatgttg acatccagg catccaaag gacatgaact
 18121 acgtgaact catctctatg atgtgttca aaatgaata ccaagtcaat ggttacctc
 18181 atagtctat caccgcga gaagtattc gtacgttgc tgcgtgatt ggtttgatg
 18241 tagaggttg tgcgaact agatgtctg tgggtactaa cctacctcc cagtagagt
 18301 ttctcaccg tgcgaacta gtatgttac cagctgttta tgttgacct gaataaca
 18361 cagaattcac cagagttaat gcaaaacct caccagtgca ccaagttaa catctatc
 18421 cactcatgta taaggcttg cootgaaatg tagtgcgat taagtatga caatgtca
 18481 ggtacaact gaagagtagg tcagacagag tcdgttgtt cctltggcg catgcttg
 18541 gcttcaactc aatgaagtag ttgtcgaag ttggacctga aagaactgt tctctgtg
 18601 aaacagctc aactgtctt tctactcat cagatactta tgcctgtcg aatcaatg
 18661 tgggtttga ctgtctctat aaccattta tgaatgatg tccagcagtg ggccttaag
 18721 gtagcctca ggtgaacct agccaactt gccagtgaca tggaaatga catgtgcta
 18781 gtgtgatgc tcatcgact agatgttag cagtcocat gtgtttttt aagcgctg
 18841 atgtgtgtt tgaataacct attatagag atgaactgag ggttaattc gcttgcaga
 18901 agttacaaa catgtgtgtg aagtctgat tgcctgtga taagtcca gttatcaga
 19021 aatgtgaaa tccaagctt acatgtgtg tgcctcagg tgaagtga tggaaatct
 19081 agatgtca gcaatagct gacaagctt acaaatga ggaactctc tatctatg
 19141 ctacacata cgaataatc atgtgtgtg ttgttgtt ttgaatgtg aactgtacc
 19201 ttaccacagc caatgcaat gctgtgaggt ttgacacag agctgtgca aactgtacc
 19261 taccagctg tgaatgtgt agtttgtatg tgaataagc gttctgcca actccagct
 19321 tgcataaag tgaattact aatttaagc aattgcaat tttttaact tctgtagtc
 19381 ctgtgtgctc tcatgcaaa caagtgtgt cgaataga ttatgtcca tctaaatctg
 19381 ctaagtgtat tacacgatgc aatttaggtg gctgtgttg cagaacctat gcaatgagt

Fig. 10. Cont.

19441 accacacgta ctggatgaca tataataga tgattctgc tgatttagc ctatgattt
 19501 acaacaact tgaactat acacttga taactttac caggttaacg agtttagaaa
 19561 atggcgcta taactgtt ataagagc acctgtatgg acacgcgc gacgacctg
 19621 tttaactat taatactg attaagctt aggtatagg tatgtatgg gagactctg
 19681 aaataagac acaactctt attaatgtt catgttagt ttggctaaq gtaacatta
 19741 aacatgagc agaatcttg aaacaaata attgggtgt tgatacgtt gctaatactg
 19801 taacttggc ctacaaaga gacgccaag cacatgtac taacaaggt gtctgcaca
 19861 tgaactact tgcacaaag ctactcaga gacgtgtctc ttaactact gctgtgtt
 19921 atgtatagt ggaagagag gtagacttt ttgaagac ccgtaatgt gtttaata
 19981 caagaggtt agccaaggt ctacacct caaaggacc agcaagctt aggtcaatg
 20041 gactcattt atttggaga taagaaaa caagtttaa gctattaa agatgagc
 20101 gctattctt accatgtct gaaactact ttaactagc cagaactta gagattta
 20161 gctatgacc aaatatgaa actgacttc tggatgcgc tatgatgaa ttaataagc
 20221 actatagct tgaaggtat gctctgaac acatogtta tggagattc agtcatgac
 20281 aacttggcg ttctattta atgttagct tagccaagc ctcaaatg taocaacta
 20341 aattagagg ttattacact atggcagca cagtgaaaa ttaactata acagatgoc
 20401 aaacagttc atcaaaatg gtgtgtctg tgattgat ttaactgat gaattgtcg
 20461 gataataaa gtaacaagt ttgtcgtga tttaaaat ggtcaaggt scaattgact
 20521 atgtgaat ttaactatg ttgtcgtga agtatgaca ttgtgaacc ttataccaa
 20581 aactcagc agtcaagc tggcaacag ggtgtggat gctaactgt tacaatgac
 20641 aagaatgct tottgaag tggaccttc agaatatgt tgaatgct gttatacca
 20701 aaggaatat gatgaatg gaaagtata tcaactgtg tcaatactta gataacca
 20761 cttaactgtt acccaaac atgagatta tcaacttgg tctgtctct gataaaggag
 20821 ttgcccagg taactctgt ctacgaact gttgcaac ttgtcactt aattggagc ttgtcgatt
 20881 cagctotaa tgaactgtg tccagcagc attctactt aattggagc ttgtcgatt
 20941 taactatgaa taataatg gaactatta tttagatat gtaagacct agtaaccaac
 21001 atggacaaa agaatagac totaaagag gtttttca ttaattgtt ggaattaa
 21061 agcaaaact agcctgggt ggttctatg ctgttaagt aacagactt tottggatg
 21121 ctgaccttta caagcttatg ggcattctc catgtggac agcttttgt acaatgtaa
 21181 atgactgac atcgagaaga tttaaatg ggcatacta tottggcag ccgaaggac
 21241 aaattgagc ctatcaaatg ctatgaact acattttgt gaggacaac aatcctatc
 21301 atgtctctt ctatcaact ttgtacac gcaaatctc tottaatia aggaagactg
 21361 ctgaatgt tottaagag aatcaatca atgatgat ttaattctt ctggaagag
 21421 tggagctat ctatagaga acaacagag ttgtgttct aagtgatatt ctgttaacg
 21481 actaaacaa catgtttatt ttctattat ttctactct cactgaact ctgttaacg
 21541 accgtggac caattttgat ttgttaag ctctaatta cactcaact acttcatc
 21601 tggcgggggt ttaactatct gatgaattt tttagatcaga caactttat ttaactagg
 21661 attattttct tcaattttt tgaatggtt caggtttca taactaat catacgtttg
 21721 gcaacctgtt aagaaagta ttattttgc tggcaacag aaatcaatg
 21781 ttgtccgggt ttgggtttt gttctaca tgaacaaca gtaacgtcg ggtattta
 21841 ttaacaattc taactaatt gttatagag catgtaactt tgatttgtt gacaacctt

Fig. 10. Cont.

21901 tcttctgtct ttctaaacct atcgtgtcac agacacatc tatgatcttc gataatgcst
 21961 ttaattctgc ttctcgatcc agctctgag ccttttcgct tgaattctca gaagaatcga
 22081 tgaattttta acacttttca gaggtttgtt ttaaaataaa agatgggttt cctcatgttt
 22081 ataaaggcta tcaactcata gatatgtctc tgaatctacc ttatgggttt acacttttga
 22141 aacctatttt taagtgttgt ctttgtatta agattacaaa tttagagattc attctatcag
 22201 cctttctaac tgcctaaagc attttgggca ogtctatgag tgcctatttt gtgtgtcatt
 22261 taagtcacaa tacaatttat cttcaattag atgamaatgg taadaatcaca ggtgtgttg
 22321 attgtctaa aaatccactt gctgaactca atgtctctgt taagaagctttt gtagatgaca
 22381 aagaattta ccaagacctc asitttcaggg ttctctccct aggaagatgtt gtagatcc
 22441 caattatc aaacttgtct ccttttgggg aggtttttta tgcactaaa ttcctcttgg
 22501 tctatgagtg gagaagaaa aaattttcga atttttggg ttgcacttaa tgcctctaca
 22561 actcaact ttcttaaaaa tttaattgct atgggtgttc tgcactaaag ttgaatgatac
 22621 ttgtctctcc caatgtctat gtagattctt ttgtagtcaa gggagatgat ggaagacaa
 22681 taggcacagg caaactgggt gctatttgct attacaatta taatttgcca gatgattca
 22741 cttgtcttgg ccttgccttgg aatactagg aacttgatgc caattcaact ggaattata
 22801 attataaata tagttatctt agacatggca agcttaggac ctttgagaga gacatatca
 22861 atgtgacctt ctcctctgat ggaataacct gaacccaac tgcctttaat tgttatggc
 22921 catgaatga ttatggtttt tacaccacta ctggcatgg ctaccacct tacagatttg
 22961 tagtaacttc ttttgaact tttaaa-gaac cggccacagg ttgtggacca aaattatcca
 23011 cggaccttat taagaacag tgtgtcaatt ttaattttaa tggactccat ggtactgggtg
 23161 ttcttaactc ttccgttga gatctctaac cattttcaaa atttggcctt gattttctgg
 23221 attttg9999 tgaagtgtga attctctaac catctgaaat attagacatt tcaacttggc
 23281 tatacaaga gtttaactgc actgagtgtt ctacagcaat tcaatgagat caactcaaac
 23341 agacttggcg tctaatctgc actgagaaaca atgtattcca gactcaagca gctgtctta
 23401 tagagctgta gcatgtgac actctctatg agtgcgacat tctatttga gctgtcatt
 23461 ttgtctatga caatacagtt tctttttatc gtagtactag ccaaaatct attgtgctt
 23521 atactatgc tttagtgtct gatagtctaa ttgcttact taataacac attgtgctt
 23581 cctcaactt tcaattagc attactacag aagtaatgoc tgtttctag cctaaact
 23641 ccgtagatgc taatgtgac attctggagc attctactga atgtctaat tgtgtctcc
 23701 taattgtgat ttcttgaca caactaatc ttgcacttc agtatgct cctgaacag
 23761 atcgcaaac actgtaagt ttcttcacaa tattactga cctctaaag ccaacttga
 23821 aatttttgg actgttttaatt ttttcacaaa aggtgaact cgtgatgct ggtttcatga
 23881 atatttttt tagagctta cttgttaata atgtgacat tctcatgtt ggcgagaagt
 23941 agcaattatg caaatgctta gttgatata atgtgagaa tctcatgtt gctcacactg
 24001 tcaatggact tacaqtgttg ccaacttgcg gatgacat ttgtctgggc gctgctctc
 24061 ctgtctagt tagtgttact gcaactgtgt gattgacat ttgtctgggc gctgctctc
 24121 taactacttt ttactatcaa atgagatata gtttcaatgg caatggagt acccaaatg
 24181 ttctctatga gaacaaaaa caaatgcca tccattttat caaggcatt ttgcaaatc
 24241 aagaactact tacaacaaa tcaatgcat ttggcagagt gaaagcatt tttaacaga
 24301 atgtctaaagc attaaacaca ctgttttaac aactttagctc taattttggt gcaatttcaa

Fig. 10. Cont.

24361 gtgtgtctaa tgaatacct tgcgaattg ataaatoga ggcgagagta caaattgaca
 24421 ggttaattac aggaagacct caaagcttc aaactatgt aacaacaa caatcaagg
 24481 ctgtgaatc aggggtctt gctaacttg gctactaa aatgtctgag tgttgttgg
 24541 gaacatacaa agagttgac ttcttgaa agggctaca ccttatctcc ttccacaag
 24601 cagcccccga tgcgtgttc ttccacatg tgcgtatgt gccatccag gagaggaact
 24661 tccacacagc gccagcaat ttcttgata cagagagaa ctctctctc caaagttt
 24721 ttgtgttaa tgcacattt gttctata cagagagaa ctctctctc caaagttt
 24781 ttactcaga caatacatt gtccacaa atgtgtatg cgttatggc atcaataa
 24841 acacagttt tcatctctg caactagc ttgactcat caagaagc ctgacaagt
 24901 actccaaaa tcatctcga ccaagtgtt atcttgoga caatcagc attaacgtt
 24961 ctgtccatc caatcaaaa gaattgacc gccatga gtcgctaa atttaagt
 25021 atctactcat tgaactcaa aatttgaa actatgaca atatataa tggctatg
 25081 atgtttgct cgtgtcatc gctggacta ttgcaatgc catgttaca actttgctt
 25141 gtgcatgac tagttgtgc agttgctca aggttgatg cctgttgtt tcttgctca
 25201 agtttgata ggttgactt ggcacgttc caaaggggt caattacat tacaactaa
 25261 cgaacttatg gattgttta tgactttt tactctaga tcaattact cacagcaat
 25321 aaaaattgac aatgtcttc ctgcaatgc tggctatg caagaaga tacgttga
 25381 agctccatc cctttggat gctgtttat tggcttga ttcttgctg ttttcagaa
 25441 gttccaaaa ataattggc tcaataaag atgcagta gccattata agggctcaa
 25501 gtctattgc aatttactg tctatttgt taccatcat tcaactttt tgcgttcgc
 25561 tgcaggtatg gagcgcaat ttgtactgt gctttgtg atgtatctc tgaatgac
 25621 caacgactg agaattata ttgtactgt gctttgtg agtgcaat ccagatcc
 25681 atactttat gatgcaact actttgttg ctgcaaca catcaatg attcaatc
 25741 accattaac atgtgcacag atacaaatg cgttactgaa gctgaagggt ttcaaac
 25801 aaactcaaa gaagcacac aaattgttg ttatttag aatggact cagggttaa
 25861 agactatgc gtgtgcatg gctattcac cgaatttgc taccatctg agcttgtaa
 25921 aattactaca gaacagcta ttgaatacg tacaatctc tccattaca agcttgtaa
 25981 agaccacac aatgtgaaa taccacaaat cgaagcttc tccaggttg ctaatccag
 26041 atgtgatac attatgatg agccagcac gaactatgc ggcctctgt aagacaaga
 26101 aatgtatgc gaactatgt atcatctgt ttgganga gcacacag taatgttaa
 26161 tagctactt atttttgtt acgttgtgt agcttgatg atcttgca agctacag ccaactta
 26221 tgcgtctga ttgttggtt agcttgatg ttaaatctt gaactctct cgtatctct
 26281 ggtttacgc taactgaaa taactatgt taactatgt ggaaggttc gttatcgt
 26341 ggttcaagc aactaatc tatattcat ctgttgaa atttaactt gttatcgt
 26401 gaagcaagc ttactattc ctgttgagay cttaaacac tcttgaaat atggaacta
 26461 gtaavagttt tctattctc acctgagtt atctaac attttgcta ttctaatc
 26521 aacagtttt tctattctc acctgagtt ttctctgc tcttggtcc agtaactc
 26581 gctgttttc tcttgctgc tcttcacga attaattgg tgaactggc gattgact
 26641 gaaatggctt gaaatggc gaaatggc atgtatg tctgtcttc cttaagctg
 26701 ttgtgtctc cccgtctac ggttgatc aaccagaa caaacattc tctaatgt
 26761 cctctccggg ggaactaatt ggcagacgc ctaatgaaa tgaacttgt cat'tgggtg

Fig. 10. Cont.




26821 gtaacatc atggctcaact gagaatggcc ggacactccc tagggccgtg tgacattaaag
 26881 gaccgcgcaa aagagatcac ttgggtacaa tcaacagcc ttctttatca caaataggag
 26941 ggctggcagc ggtgagcagc tgattcagc ttgtgtgat acaacccgtt ccgtattgga
 27001 aactataaact taatatcaga caacgcggt agcaacgaca atatccgtt gctattgga
 27061 taagtgcaca cagatgtttc actctgttc ttccacggt acaattagca agtatgtat
 27121 tatcatcaga agacttttca gattgtgat ttgaaattt gaagttataa gaatttcaat
 27181 actgagacaa ttatttaagc ctctacaata acatgaatat tccagcttag atgatgaag
 27241 adgtatggag ttagattatc ctcaaaacga caatgaatat tatctctc ctgacttga
 27301 ttgtattatc actttgcga ctatatcaat atcagagtg tctaaagt agactttga
 27361 taataaaga actttgcga ctatgaacat acagagcag tctacaatt agactttg
 27421 ctgacaataa atttgacta ctgtgacta gacacact ttgttttct ttgtctgag
 27481 aaagagaggt tcaacaagag ctgtgtgcaa gatcagttt acmaattt tctatagac
 27541 aaagagaggt tcaacaagag ctgtgtgcaa gatcagttt acmaattt tctatagac
 27601 tttaatact ttgttcacg attatagag acactttct catgttgtt tctatagac
 27661 ctctatattg ttgttttag ccttttctgt attcttgtt taataatgc tttaattg
 27721 ttgttttca ctgaaatcc aggttatca agaatctgt accaaagtct aaacgaact
 27781 gaactcttc atgttttga ctgttatct tctatgact tgaatgact aaactagga
 27841 ggcgtgcca tctataaac ctatgtgtt ttgaatcct tgraagttac aaactaggg
 27901 gtaataatg ttgttttgc ctctaggaaa ggttttacct ttctatgat
 27961 ggcacactt ggttcaaca tgcacacta atgtactat caacttcaa gatccagtg
 28021 ttgtgtggt tatagttagg tgtgtgaac ttcatgaag tcaacaaact gctgcattg
 28081 ggcgtgaat ttgttttca aataacgaa caattaaaa tgcctgataa tggaccocaa
 28141 tcaaaaac gtagtgccc atgcattaca ttgtgtgac ccacagattc aactgcaat
 28201 aaacpaaat gagagcgaa tggggcagg ccaaaacgc gcgcagccca aggtttacc
 28261 aataatagc gcttttgtt cacagtctc actcagatc gcaagagga acttagattc
 28321 ctgcaggcc aggggtttc aatacaacc aatagtgtc cagatgaca aatggattac
 28381 taccgaag ctaccggtc agtttgtgt ggtgacgca aatgaaga gtcagccc
 28441 agagttact tctattacct aggaactgg ccagaagct cacttccca cggcgtaac
 28501 aaagaggca ttgatgggt tgcactgag ggagcttga atacacca agaccact
 28561 ggcaccgca acttaataa caatgtgc accgtgtac aacttctca aggaacaa
 28621 ttgcacaa gcttctacg accgtgtgc agagcgga gtcagcttc ttctgctc
 28681 tccacgca tggcggtta ttcaagaat tcaactctg gscagatg ggtgaattc
 28741 cctgctcga ttgctagcg aggtgtgaa actgcctcg aacacaggt tcaacacaa
 28801 ttgaaccag ttgagcga agtttttgt aaagcccaa aacacaggt tcaacacaa
 28861 actaagaat ctgctgtga ggcattcaa aagcctcgc aaaaactac ccaacacaa
 28921 gggaaccaag tcaactcag atttggaga cgttgtccag acaaccca aggaatttc
 29011 ttgtgtccaa gttcctctg attcttgg atgtacaga ttggcaga agtcaact
 29101 ttgggaact ggcgtgaact tcatggagc attaatgg atcaaaaat tcaaatc
 29161 aagacacaa tcaactgtt gaaagac attgacgat acaaaact tcaacacaa
 29221 gagctcaaa aggcacaaa gaaaagact gatgaagtc agctttgac gaaagacaa

Fig. 10. Cont.

29281 aagaagcgc ccactgtgac tcttctctc ggggtgaca tggatgatt ctccagacaa
29341 ctccaatt ccatggtgg agctctgct gat'caactc aggcataaac actcatgtg
29401 accacaaag ggaatgggc taigtaaacg ttctgcaat tccgttaacg atacatgac
29461 tactctgtg cagaatgaat tctcgttaact aaacagacaa agtaggttta gtaacctta
29521 attccacata gcaatcttta atcaatggtt aacattaggg agactctgaa agagccacca
29581 cattttcacc gaagtcacgc ggaatgacgt cgaggtgaca ggaataatg ctagggaag
29641 ctgctcatac ggaagagccc taatgtgtaa aattatatt agtagtcta tcccatgtg
29701 attttaatag ctctctagga gaatgacaaa aaaaaaaaa a

34/36

Fig 11






Fig 13

